<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Inorg Chem</journal-id><journal-id journal-id-type="iso-abbrev">Inorg Chem</journal-id><journal-id journal-id-type="publisher-id">ic</journal-id><journal-id journal-id-type="coden">inocaj</journal-id><journal-title-group><journal-title>Inorganic Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0020-1669</issn><issn pub-type="epub">1520-510X</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40325346</article-id><article-id pub-id-type="pmc">PMC12093293</article-id>
<article-id pub-id-type="doi">10.1021/acs.inorgchem.5c00579</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Gold Acyclic
Diaminocarbene Complexes as Selective
and Potent Agents for Multitarget Cancer Therapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Gil-Moles</surname><given-names>Mar&#x000ed;a</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes3" ref-type="notes">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Aliaga-Lavrijsen</surname><given-names>Melanie</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes3" ref-type="notes">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Montanel-P&#x000e9;rez</surname><given-names>Sara</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Marzo</surname><given-names>Isabel</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Villacampa</surname><given-names>M. Dolores</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath6"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0553-0695</contrib-id><name><surname>Gimeno</surname><given-names>M. Concepci&#x000f3;n</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Departamento
de Qu&#x000ed;mica Inorg&#x000e1;nica, <institution>Instituto
de S&#x000ed;ntesis Qu&#x000ed;mica y Cat&#x000e1;lisis Homog&#x000e9;nea
(ISQCH) CSIC-Universidad de Zaragoza</institution>, Zaragoza 50009, <country>Spain</country></aff><aff id="aff2"><label>&#x02021;</label>Departamento
de Bioqu&#x000ed;mica y Biolog&#x000ed;a Celular, <institution>Universidad de Zaragoza</institution>, Zaragoza 50009, <country>Spain</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>gimeno@unizar.es</email>.</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>05</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>19</day><month>05</month><year>2025</year></pub-date><volume>64</volume><issue>19</issue><fpage>9608</fpage><lpage>9620</lpage><history><date date-type="received"><day>08</day><month>02</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>04</month><year>2025</year></date><date date-type="rev-recd"><day>11</day><month>04</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0014" id="ab-tgr1"/></p><p>Gold acyclic diaminocarbene
(ADC) complexes represent a promising,
yet underexplored, class of chemotherapeutics. ADCs offer superior
flexibility and stronger sigma donation compared with traditional
N-heterocyclic carbenes, making them ideal ligands for stable gold-based
drugs. In this study, a series of gold ADC complexes were synthesized
via the nucleophilic addition of amines to [AuCl(CNCy)], yielding
three structural families: gold-chloride-ADC (chiral and achiral),
bis(carbene), and thiolate-gold-ADC complexes. Extensive characterization,
including X-ray diffraction, revealed noncovalent interactions, such
as hydrogen bonding and aurophilic contacts, that significantly shape
their molecular architecture. These complexes exhibit potent cytotoxicity
(IC<sub>50</sub> in submicromolar) against drug-resistant cancer cell
lines (A549, HCT116 WT, Jurkat, MiaPaca2), with some showing high
selectivity toward cancer cells over healthy lymphocytes (selectivity
index up to 74). Mechanistic investigations indicate that they disrupt
mitochondrial function, elevate reactive oxygen species (ROS), and,
in the case of bis(carbene) species, bind DNA. Apoptosis is induced
at low concentrations, while higher doses trigger alternative death
pathways. Notably, they also strongly inhibit thioredoxin reductase
(TrxR), comparable in potency to auranofin. The combination of ROS
induction, DNA interaction, mitochondrial disruption, and TrxR inhibition
highlights the multitargeted anticancer potential of gold-ADC complexes
and supports their further development as selective and effective
chemotherapeutic agents.</p></abstract><abstract abstract-type="short"><p>Gold acyclic
diaminocarbene (ADC) complexes represent a
promising, yet underexplored, class of chemotherapeutics.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution>Ministerio de Ciencia, Innovaci&#x000c3;&#x000b3;n y Universidades</institution><institution-id institution-id-type="doi">10.13039/100014440</institution-id></institution-wrap></funding-source><award-id>PID2022-136861NB-I00</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Gobierno de Arag&#x000c3;&#x000b3;n</institution><institution-id institution-id-type="doi">10.13039/501100010067</institution-id></institution-wrap></funding-source><award-id>E07_23R</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ic5c00579</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ic5c00579</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Metal-based drugs are widely employed
in modern diagnosis and therapy,
offering innovative solutions for challenging medical conditions.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref4">4</xref></sup> Compared with pure organic molecules, these compounds combine the
unique characteristics of the metal ions with those of organic ligands,
enabling the development of multifunctional therapeutic agents with
enhanced potential. Often designed as prodrugs, metallodrugs are activated
through mechanisms such as ligand substitution, redox reactions, or
light activation.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> These properties together
with the different activation pathways grant them unique properties
and enhanced functionalities, particularly in combating cancer progression.<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup> Notably, one of their key advantages is their ability to function
as multitargeting agents.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref9">9</xref></sup></p><p>Multitarget strategies
in cancer therapy are designed to address
the limitations of single-target approaches, which frequently result
in drug resistance and diminished efficacy due to the intricate and
adaptive nature of cancer. By simultaneously targeting multiple molecular
pathways, cellular mechanisms, or tumor components, these strategies
aim to deliver more effective therapeutic outcomes.</p><p>The ongoing
search for new cancer therapies as alternatives to
platinum-based drugs, due to their severe side effects and resistance
issues, has driven interest in novel metal-based drugs with unique
biological properties and targets. Gold derivatives have garnered
attention, especially due to their ability to interact with multiple
enzymes, highlighting their potential as multitarget agents.<sup><xref ref-type="bibr" rid="ref10">10</xref>&#x02212;<xref ref-type="bibr" rid="ref13">13</xref></sup></p><p>In the development of gold chemotherapeutics, ligand design
plays
a pivotal role in addressing key challenges such as stability, cellular
uptake, and selectivity. In this sense, acyclic diaminocarbene (ADC)
ligands represent a cutting-edge class of carbene ligands, distinguished
by their open-chain, noncyclic structure featuring two nitrogen atoms
bound to a central carbene carbon. Unlike the rigid cyclic framework
of N-heterocyclic carbenes (NHCs), ADCs boast an adaptable structure
that grants exceptional flexibility and opens up a wider range of
geometries when bound to metal centers. This unique structural freedom,
combined with their high electron density, makes ADCs an invaluable
tool for catalysis, coordination chemistry, and material chemistry.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> While ADC gold complexes have well-established applications in catalysis<sup><xref ref-type="bibr" rid="ref16">16</xref>&#x02212;<xref ref-type="bibr" rid="ref21">21</xref></sup> and materials science,<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> their potential in
biological systems remains largely unexplored. However, N-heterocyclic
gold(I) carbenes have been extensively studied in medicine, particularly
as antitumor agents, with several showing promising efficacy.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref25">25</xref></sup> By comparison, there are few reports on the antitumor activity of
gold(I) and gold(III) acyclic diaminocarbene derivatives. To date,
research has been limited to a few reports, including gold(I) and
gold(III) complexes from our group,<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> those reported
by Bertrand, Bochmann, and co-workers,<sup><xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> and the bimetallic
gold&#x02013;platinum species recently reported by Scattolin, Hashmi,
and co-workers (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>).<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> A wide variation in cytotoxicity
has been observed among these derivatives, with IC<sub>50</sub> values
ranging from the high micromolar to the nanomolar range. Furthermore,
their mechanisms of action are poorly understood. To date, the evaluated
complexes have shown moderate inhibition of TrxR and low ROS production.
However, other potential biological targets have not yet been investigated.
This fact highlights that further investigation of the mechanism and
improved selectivity toward tumor cells are still needed.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Gold ADC complexes
with antitumor properties.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0001" id="gr1" position="float"/></fig><p>To address this gap, this study centers on the
synthesis of a series
of chiral and achiral gold acyclic diaminocarbene complexes with diverse
stoichiometries. Specifically, three families of complexes will be
evaluated: gold-chloride-ADC, bis(carbene), and thiolate-gold-ADC
complexes in order to determine the influence of the auxiliary ligands
in the anticancer properties as well as in stability. The cytotoxic
properties of these complexes have been rigorously evaluated across
multiple cancer cell lines as well as in healthy lymphocytes. Some
of the complexes show promising activity and selectivity, and their
mechanisms of action have been thoroughly investigated, revealing
new insights into their potential for targeted cancer therapy.</p></sec><sec id="sec2"><title>Results
and Discussion</title><sec id="sec2.1"><title>Synthesis and Characterization of Gold Complexes</title><p>One
of the most commonly used methods for synthesizing metal ADC complexes
is the nucleophilic attack of amines on isocyanide metal derivatives,<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> although other synthetic procedures have been reported.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> This approach is especially effective for gold
isocyanide complexes, which typically exhibit a strong electrophilic
character at the carbon atom of the isocyanide group, facilitating
the straightforward synthesis of acyclic diaminocarbene complexes
through reactions with amines.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup></p><p>In our investigations, we have reacted the isocyanide complex [AuCl(CNCy)]
with various amines, including those featuring pyridine substituents
and chiral structures. A nucleophilic attack occurs when the NH group
of secondary amines, such as <italic>N</italic>-(pyridylmethyl)cyclohexylamine
and di(pyridylmethyl)amine, targets the electron-deficient carbon
of the isocyanide, which serves as an electrophilic center, thus leading
to the formation of the corresponding amino carbene. Furthermore,
we have explored gold complexes with chiral amine and diamine scaffolds,
including aminoindanol and 1,2-cyclohexanediamine, as illustrated
in <xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>.</p><fig id="sch1" position="float"><label>Scheme 1</label><caption><title>Synthesis
of Gold(I) Acyclic Diaminocarbenes <bold>1</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0011" id="gr2" position="float"/></fig><p>All complexes were characterized by <sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H}-APT NMR spectroscopy (see Supporting
Information <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">Figures S1&#x02013;S8</ext-link>), IR spectroscopy,
and mass
spectrometry. For all of the complexes, the infrared (IR) spectra
showed key absorptions, including the prominent &#x003bd;(Au&#x02013;Cl)
band at approximately 325 cm<sup>&#x02013;1</sup>, the &#x003bd;(C=N)
band of the newly formed carbenes at 1587 cm<sup>&#x02013;1</sup>,
and the NH band around 2932 cm<sup>&#x02013;1</sup>. The mass spectra
exhibited molecular ion peaks corresponding to protonated or sodium-cationic
species [M + H]<sup>+</sup> or [M + Na]<sup>+</sup> or fragments arising
at the loss of the chloride ligand [M &#x02013; Cl]<sup>+</sup>. The <sup>1</sup>H NMR spectra for complexes <bold>1a&#x02013;c</bold> displayed
the expected signals without any indication of rotamers. However,
for complex <bold>1d</bold>, three distinct rotamers were clearly
observed in the signals of the tolyl group. These resonances were
simplified upon recording the spectrum in DMSO-<italic>d</italic><sub>6</sub> at elevated temperatures, up to 394 K (see Supporting Information, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">Figure S9</ext-link>). In the <sup>13</sup>C APT NMR spectra,
all signals could be distinctly assigned, including those corresponding
to the cyclohexyl moieties. Notably, the resonances for the carbene
carbon appeared at 192.8 and 193.0 ppm for complexes <bold>1a</bold> and <bold>1b</bold>, respectively. These positions are deshielded
compared to those in [AuX(NHC)] (X = Cl, Br) complexes with both aryl
and alkyl substituents (range: 172&#x02013;174 ppm). This deshielding
may be attributed to reduced electron density on the carbene carbon,
likely caused by stronger metal&#x02013;ligand interactions, lower
donor capacity of the ligand, or other contributing factors.<sup><xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup></p><p>Bis(carbene) gold complexes were achieved through the reaction
of the complex [Au(CNCy)<sub>2</sub>]OTf with the corresponding amines
(<xref rid="sch2" ref-type="scheme">Scheme <xref rid="sch2" ref-type="scheme">2</xref></xref>). In this
case, only two representative examples with the non-chiral pycolyl
derivatives were afforded in order to avoid the presence of rotamers
in the molecule.</p><fig id="sch2" position="float"><label>Scheme 2</label><caption><title>Synthesis of the Bis(carbene) Gold(I) Species <bold>2</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0012" id="gr3" position="float"/></fig><p>The characterization of complexes <bold>2a</bold> and <bold>2b</bold> was performed using techniques similar
to those applied to family
1. The NMR spectra (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">Figures S10 and S13</ext-link>) exhibit the expected resonances. Interestingly, the <sup>13</sup>C resonance for the carbene carbon appears at 205.2 and 206.1, respectively,
showing a downfield shift compared to the chloride derivatives and
even greater deshielding the related [Au(NHC)<sub>2</sub>]<sup>+</sup> complexes.<sup><xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> The mass spectra reveal, as the
most abundant peaks, the cationic [M-OTf]<sup>+</sup> at 795.4383
for <bold>2a</bold> and 814.3740 for <bold>2b</bold>.</p><p>The reactivity
of the complex [AuCl{C(NHCy)(NCy-CH<sub>2</sub>py)}]
(<bold>1</bold>) with various thiols was investigated to facilitate
the formation of the corresponding gold(I) thiolates through a substitution
reaction involving the chloride ligand. In the synthesis of gold(I)
derivatives <bold>3a&#x02013;d</bold>, a base, potassium carbonate,
is used to help with the deprotonation of the 2-thiocytosine, 2-mercaptopyridine,
2-thiouracil, and 1-thio-&#x003b2;-<sc>d</sc>-glucose, thereby promoting
the elimination of the HCl formed (<xref rid="sch3" ref-type="scheme">Scheme <xref rid="sch3" ref-type="scheme">3</xref></xref>).</p><fig id="sch3" position="float"><label>Scheme 3</label><caption><title>Synthesis of the Thiolate-Gold(I)-ADC
Complexes <bold>3</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0013" id="gr4" position="float"/></fig><p>Complexes <bold>3a&#x02013;d</bold> were characterized
by <sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H}-APT NMR spectroscopy
(see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">Figures S14&#x02013;S21</ext-link>), IR spectroscopy,
and
mass spectrometry. In the IR spectra, the disappearance of the &#x003bd;(Au&#x02013;Cl)
band confirms the loss of the Au&#x02013;Cl bond. The NMR spectra exhibit
the expected resonances for the carbene ligand, along with additional
signals corresponding to the incorporated thiolate ligands. The resonances
for the carbene carbon atoms appear around 202 ppm, which is an intermediate
chemical shift compared to those observed in Au&#x02013;Cl or bis(carbene)
gold derivatives and again downfield compared with the related [Au(SR)(NHC)]
(182&#x02013;185 ppm).<sup><xref ref-type="bibr" rid="ref37">37</xref></sup></p></sec><sec id="sec2.2"><title>Crystal Structure
Determination</title><p>Suitable crystals for
X-ray diffraction studies of complex <bold>1a</bold> were obtained
through the slow diffusion of hexane into a dichloromethane solution
of the complex. The compound crystallizes in the triclinic system
within space group <italic>P</italic>&#x00031;&#x00305;, featuring one molecule
per asymmetric unit (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A). The gold atom exhibits a linear coordination typical of
gold(I), although slightly distorted, as evidenced by the C7&#x02013;Au1&#x02013;Cl1
angle of 175.7(2)&#x000b0;. The Au&#x02013;C and Au&#x02013;Cl bond distances
are 1.993(9) &#x000c5; and 2.284(4), respectively, consistent with those
found in other organometallic gold(I) chloride derivatives with carbene
ligands.<sup><xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> The bond lengths of the carbene group, N1&#x02013;C7
at 1.333(12) &#x000c5; and N2&#x02013;C7 at 1.331(12) &#x000c5;, clearly
indicate their multiple bond character, while the N2&#x02013;C7&#x02013;N1
angle of 117.6(9)&#x000b0; approaches 120&#x000b0;, reflecting the sp<sup>2</sup> hybridization of the carbene carbon.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Molecular structure of
complex <bold>1a</bold> (A) and association
of molecules of <bold>1a</bold> in dimers through aurophilic interactions
(B).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0002" id="gr5" position="float"/></fig><p>Furthermore, as illustrated in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B, there is an intramolecular
hydrogen bond
between N3 of the pyridine and N2&#x02013;H2A of the carbene group
(N2&#x02013;H2A&#x000b7;&#x000b7;&#x000b7;N3 at 2.088 &#x000c5;, 147.05&#x000b0;).
In addition, an intermolecular aurophilic interaction between the
two gold atoms of two neighboring molecules can be observed, at a
distance of Au1&#x000b7;&#x000b7;&#x000b7;Au1 (&#x02212;<italic>x</italic>,
&#x02212;<italic>y</italic> + 1, &#x02212;<italic>z</italic>) of 3.4384(9)
&#x000c5;, shorter than the sum of the van der Waals radii of the gold
atoms.</p><p>A different structural form crystallized as a dichloromethane
solvate
from a different sample, also obtained by diffusion of hexane into
a dichloromethane solution. In this case, the compound crystallized
in the monoclinic system space group <italic>I</italic>2/<italic>c</italic>. Each asymmetric unit is composed of one molecule of compound <bold>1a</bold> and one molecule of dichloromethane. The molecule (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">Figure S22</ext-link>) is essentially the same as that in
the triclinic crystal, with similar bond distances. An important difference
is that in this crystal, there are no &#x0201c;aurophilic&#x0201d; interactions
between the gold atoms; the closest ones are more than 5 &#x000c5; apart.
Perhaps the absence of these interactions causes the gold atom to
be in a practically linear environment, less distorted than in the
triclinic crystal, C7&#x02013;Au1&#x02013;Cl1 179.3(4)&#x000b0;. The existence
of an intramolecular hydrogen bond of 2.131 &#x000c5; between the pyridinic
nitrogen and the NH of the carbene group is also observed.</p><p>The
crystal structure of complex <bold>1b</bold> is shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>. Its structural
features closely resemble those of complex <bold>1a</bold>, with a
nearly linear Cl1&#x02013;Au&#x02013;C1 angle of 177.23(9)&#x000b0; and
a slightly longer Au&#x02013;C1 bond length of 2.071(3) &#x000c5;, likely
attributed to the presence of more aromatic substituents on the nitrogen
atom of the carbene moiety. Additionally, a short intramolecular N&#x02013;H&#x000b7;&#x000b7;&#x000b7;N
hydrogen bond of 2.143 &#x000c5; is observed. Notably, there are no significant
Au&#x000b7;&#x000b7;&#x000b7;Au interactions, with the shortest Au&#x000b7;&#x000b7;&#x000b7;Au
distance measuring 5.381 &#x000c5;.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Molecular structure of complex <bold>1b</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0003" id="gr6" position="float"/></fig><p>In the crystal structure of complex <bold>3c</bold> (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>A), the
gold atom adopts a
slightly distorted linear geometry with a C1&#x02013;Au1&#x02013;S1
angle of 175.9(3)&#x000b0;. The Au&#x02013;S (2.302(3) &#x000c5;) and Au&#x02013;C
(1.962(15) &#x000c5;) bond lengths are consistent with those observed
in other derivatives containing the S&#x02013;Au(I)&#x02013;C fragment
and are comparable to those in the parent complex <bold>1a</bold>.
The C&#x02013;N bond lengths in the carbene group (N1&#x02013;C1:1.360(15)
&#x000c5;, N2&#x02013;C1:1.366(15) &#x000c5;) are shorter than typical single
bonds, consistent with significant double-bond character.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Molecular structure
of complex <bold>3c</bold> (A) and association
of molecules of <bold>3c</bold> in pairs through hydrogen bonding
(B).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0004" id="gr7" position="float"/></fig><p>The angles around the C1 atom
of the carbene (112.5&#x000b0;, 123.4&#x000b0;,
and 124.0&#x000b0;) indicate a somewhat distorted trigonal planar geometry,
which is likely due to steric effects. No metal&#x02013;metal interactions
are present, but the molecules associate in pairs through intermolecular
hydrogen bonding. In <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B, hydrogen bonds between the nitrogen and oxygen atoms of
the thiouracil group in one molecule and the oxygen and nitrogen atoms
of the same group in another molecule are illustrated (N5&#x02013;H5&#x000b7;&#x000b7;&#x000b7;O1
[&#x02212;<italic>x</italic>, &#x02212;<italic>y</italic>, &#x02212;z]:
1.923 &#x000c5;, 166.23&#x000b0;). Additionally, an intramolecular hydrogen
bond is observed involving the NH group of the carbene and the nitrogen
atom of the pyridine ring (N2&#x02013;H1&#x000b7;&#x000b7;&#x000b7;N3: 2.003
&#x000c5;, 147.56&#x000b0;).</p></sec><sec id="sec2.3"><title>Cytotoxicity and Selectivity Studies</title><p>As an initial
step in studying the cytotoxic properties of the complexes, stability
studies were conducted to assess their behavior in biological media.
First, the stability was studied by NMR (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">Figures S23&#x02013;S32</ext-link>), revealing that the complexes remain stable
in DMSO solution over extended periods. This stability is attributed
to the low affinity of gold for oxygen-donor ligands, preventing exchange
reactions with the solvent. Second, solutions of the target compounds
were prepared in DMSO and then diluted in phosphate-buffered saline
(PBS). UV&#x02013;visible measurements were taken at multiple time
points over a 24 h period, while the solutions were incubated at 37
&#x000b0;C to monitor for any changes or formation of new species in
the assay medium. All compounds tested demonstrated stability under
these simulated biological conditions (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">Figures S33&#x02013;S42</ext-link>). The most distinctive feature is the absence
of the plasmon band (500&#x02013;600 nm) associated with gold nanoparticles,
confirming the stability of the complexes in solution.</p><p>To evaluate
the potential anticancer properties of the gold complexes, four cancer
cell lines representing some of the most aggressive cancers were selected:
A549 lung carcinoma, MiaPaca2 pancreatic cancer, HCT116 WT colon adenocarcinoma,
and Jurkat T-cell leukemia (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>IC<sub>5O</sub> Values for Complexes <bold>1&#x02013;3</bold> in the Different Cancer Cells Measured at 24 h
(&#x003bc;M)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="&#x000b1;"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">A549</th><th style="border:none;" align="center" char="&#x000b1;">HCT116 WT</th><th style="border:none;" align="center">Jurkat</th><th style="border:none;" align="center">MiaPaca2</th></tr></thead><tbody><tr><td style="border:none;" align="left">CisPt<xref rid="t1fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">114&#x000a0;&#x000b1;&#x000a0;9</td><td style="border:none;" align="char" char="&#x000b1;">1.2&#x000a0;&#x000b1;&#x000a0;0.1</td><td style="border:none;" align="left">10.8&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="left">76.5&#x000a0;&#x000b1;&#x000a0;7.4</td></tr><tr><td style="border:none;" align="left">AF<xref rid="t1fn1" ref-type="table-fn">a</xref><sup>,</sup><xref rid="t1fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">7.59</td><td style="border:none;" align="char" char="&#x000b1;">7.8&#x000a0;&#x000b1;&#x000a0;0.9</td><td style="border:none;" align="left">1.4</td><td style="border:none;" align="left">2.34</td></tr><tr><td style="border:none;" align="left"><bold>1a</bold></td><td style="border:none;" align="left">4.3&#x000a0;&#x000b1;&#x000a0;0.7</td><td style="border:none;" align="char" char="&#x000b1;">2.45&#x000a0;&#x000b1;&#x000a0;0.07</td><td style="border:none;" align="left">0.8&#x000a0;&#x000b1;&#x000a0;0.1</td><td style="border:none;" align="left">3.1&#x000a0;&#x000b1;&#x000a0;0.8</td></tr><tr><td style="border:none;" align="left"><bold>1b</bold></td><td style="border:none;" align="left">9.1&#x000a0;&#x000b1;&#x000a0;1.6</td><td style="border:none;" align="char" char="&#x000b1;">&#x000a0;</td><td style="border:none;" align="left">4.1&#x000a0;&#x000b1;&#x000a0;0.9</td><td style="border:none;" align="left">8.6&#x000a0;&#x000b1;&#x000a0;1.9</td></tr><tr><td style="border:none;" align="left"><bold>1c</bold></td><td style="border:none;" align="left">1.3&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="char" char="&#x000b1;">9.6&#x000a0;&#x000b1;&#x000a0;1.7</td><td style="border:none;" align="left">6.76&#x000a0;&#x000b1;&#x000a0;0.33</td><td style="border:none;" align="left">3.4&#x000a0;&#x000b1;&#x000a0;0.5</td></tr><tr><td style="border:none;" align="left"><bold>1d</bold></td><td style="border:none;" align="left">21.6&#x000a0;&#x000b1;&#x000a0;1.4</td><td style="border:none;" align="char" char="&#x000b1;">2.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="left">8.1&#x000a0;&#x000b1;&#x000a0;1.3</td><td style="border:none;" align="left">9.9&#x000a0;&#x000b1;&#x000a0;1.1</td></tr><tr><td style="border:none;" align="left"><bold>2a</bold></td><td style="border:none;" align="left">13.4&#x000a0;&#x000b1;&#x000a0;1.0</td><td style="border:none;" align="char" char="&#x000b1;">0.61&#x000a0;&#x000b1;&#x000a0;0.11</td><td style="border:none;" align="left">0.65&#x000a0;&#x000b1;&#x000a0;0.01</td><td style="border:none;" align="left">1.75&#x000a0;&#x000b1;&#x000a0;0.15</td></tr><tr><td style="border:none;" align="left"><bold>2b</bold></td><td style="border:none;" align="left">0.82&#x000a0;&#x000b1;&#x000a0;0.05</td><td style="border:none;" align="char" char="&#x000b1;">1.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="left">0.50&#x000a0;&#x000b1;&#x000a0;0.02</td><td style="border:none;" align="left">0.38&#x000a0;&#x000b1;&#x000a0;0.10</td></tr><tr><td style="border:none;" align="left"><bold>3a</bold></td><td style="border:none;" align="left">0.43&#x000a0;&#x000b1;&#x000a0;0.01</td><td style="border:none;" align="char" char="&#x000b1;">0.95&#x000a0;&#x000b1;&#x000a0;0.14</td><td style="border:none;" align="left">5.2&#x000a0;&#x000b1;&#x000a0;0.9</td><td style="border:none;" align="left">3.30&#x000a0;&#x000b1;&#x000a0;0.25</td></tr><tr><td style="border:none;" align="left"><bold>3b</bold></td><td style="border:none;" align="left">2.3&#x000a0;&#x000b1;&#x000a0;0.5</td><td style="border:none;" align="char" char="&#x000b1;">4.22&#x000a0;&#x000b1;&#x000a0;0.25</td><td style="border:none;" align="left">0.79&#x000a0;&#x000b1;&#x000a0;0.03</td><td style="border:none;" align="left">2.0&#x000a0;&#x000b1;&#x000a0;0.5</td></tr><tr><td style="border:none;" align="left"><bold>3c</bold></td><td style="border:none;" align="left">2.04&#x000a0;&#x000b1;&#x000a0;0.19</td><td style="border:none;" align="char" char="&#x000b1;">2.7&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="left">3.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td style="border:none;" align="left">1.60&#x000a0;&#x000b1;&#x000a0;0.17</td></tr><tr><td style="border:none;" align="left"><bold>3d</bold></td><td style="border:none;" align="left">1.30&#x000a0;&#x000b1;&#x000a0;0.12</td><td style="border:none;" align="char" char="&#x000b1;">1.09&#x000a0;&#x000b1;&#x000a0;0.03</td><td style="border:none;" align="left">0.26&#x000a0;&#x000b1;&#x000a0;0.03</td><td style="border:none;" align="left">1.5&#x000a0;&#x000b1;&#x000a0;0.2</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>AF auranofin.</p></fn><fn id="t1fn2"><label>b</label><p>Literature values.<sup><xref ref-type="bibr" rid="ref38">38</xref>&#x02212;<xref ref-type="bibr" rid="ref43">43</xref></sup></p></fn></table-wrap-foot></table-wrap><p>The data revealed substantial
cytotoxicity across all measured
compounds, highlighting distinct activity profiles within each family.
In the first family, where chloride serves as the auxiliary ligand,
compound <bold>1a</bold> displayed excellent activity across all cell
lines, being more active against leukemia cells. In contrast, compound <bold>1b</bold> exhibited lower activity overall but was also more active
against leukemia cells. Among the chiral compounds, aminoindanol-substituted
variant <bold>1c</bold> exhibited selectivity for lung and pancreatic
cancer, while compound <bold>1d</bold> targeted more selectively colon
cancer. This diversity highlighted the critical role played by the
ADC ligand.</p><p>The bis(carbene) derivatives showed remarkable cytotoxic
activity,
likely due to their cationic nature, which could enhance cellular
uptake. Gold(I) thiolate-carbenes emerged as especially potent, with
compounds bearing thiocytosine (<bold>3a</bold>) and thioglucopyranosato
(<bold>3d</bold>) ligands demonstrating IC<sub>50</sub> values in
the submicromolar range.</p><p>Overall, gold(I) thiolate and gold
bis(carbene) complexes exhibited
superior cytotoxicity compared with other Au(I) complexes with chloride
ligands. This emphasized the critical impact of ligand choice on cytotoxic
efficacy.</p><p>We extended our study to healthy human lymphocytes
donated by the
Blood and Tissue Bank of Aragon, to assess the selectivity of our
compounds by comparing IC<sub>50</sub> values between lymphocytes
and Jurkat cells. This approach allowed us to determine the tumor
selectivity of each compound. Notably, all compounds except complex <bold>3c</bold> displayed greater toxicity toward tumor cells than toward
healthy cells. Complexes <bold>1d</bold>, <bold>2a</bold>, <bold>3d</bold>, and especially <bold>3b</bold> stood out, demonstrating exceptionally
high selectivity and remarkably low IC<sub>50</sub> values in tumor
cells. <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> provides
a detailed comparison of IC<sub>50</sub> values for Jurkat cells and
healthy lymphocytes along with the selectivity index for each compound.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>IC<sub>5O</sub> Values for Complexes <bold>1&#x02013;3</bold> in the Jurkat Cancer Cells and Healthy Lymphocytes
Measured at 24 h (&#x003bc;M) and Selectivity Index (SI)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center" char="&#x000b1;">Jurkat</th><th style="border:none;" align="center" char="&#x000b1;">lymphocytes</th><th style="border:none;" align="center" char=".">SI</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>1a</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.82&#x000a0;&#x000b1;&#x000a0;0.13</td><td style="border:none;" align="char" char="&#x000b1;">3.86&#x000a0;&#x000b1;&#x000a0;0.25</td><td style="border:none;" align="char" char=".">4.70</td></tr><tr><td style="border:none;" align="left"><bold>1c</bold></td><td style="border:none;" align="char" char="&#x000b1;">6.76&#x000a0;&#x000b1;&#x000a0;0.33</td><td style="border:none;" align="char" char="&#x000b1;">10.64&#x000a0;&#x000b1;&#x000a0;1.12</td><td style="border:none;" align="char" char=".">1.57</td></tr><tr><td style="border:none;" align="left"><bold>1d</bold></td><td style="border:none;" align="char" char="&#x000b1;">8.1&#x000a0;&#x000b1;&#x000a0;1.3</td><td style="border:none;" align="char" char="&#x000b1;">49.4&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="char" char="."><bold>6.13</bold></td></tr><tr><td style="border:none;" align="left"><bold>2a</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.65&#x000a0;&#x000b1;&#x000a0;0.01</td><td style="border:none;" align="char" char="&#x000b1;">5.9&#x000a0;&#x000b1;&#x000a0;0.7</td><td style="border:none;" align="char" char="."><bold>9.01</bold></td></tr><tr><td style="border:none;" align="left"><bold>2b</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.50&#x000a0;&#x000b1;&#x000a0;0.02</td><td style="border:none;" align="char" char="&#x000b1;">1.51&#x000a0;&#x000b1;&#x000a0;0.16</td><td style="border:none;" align="char" char=".">3.02</td></tr><tr><td style="border:none;" align="left"><bold>3a</bold></td><td style="border:none;" align="char" char="&#x000b1;">5.2&#x000a0;&#x000b1;&#x000a0;1.0</td><td style="border:none;" align="char" char="&#x000b1;">11.7&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="char" char=".">2.27</td></tr><tr><td style="border:none;" align="left"><bold>3b</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.79&#x000a0;&#x000b1;&#x000a0;0.03</td><td style="border:none;" align="char" char="&#x000b1;">58.2&#x000a0;&#x000b1;&#x000a0;0.9</td><td style="border:none;" align="char" char="."><bold>73.68</bold></td></tr><tr><td style="border:none;" align="left"><bold>3c</bold></td><td style="border:none;" align="char" char="&#x000b1;">3.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td style="border:none;" align="char" char="&#x000b1;">0.52&#x000a0;&#x000b1;&#x000a0;0.11</td><td style="border:none;" align="char" char=".">0.14</td></tr><tr><td style="border:none;" align="left"><bold>3d</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.26&#x000a0;&#x000b1;&#x000a0;0.03</td><td style="border:none;" align="char" char="&#x000b1;">2.19&#x000a0;&#x000b1;&#x000a0;0.01</td><td style="border:none;" align="char" char="."><bold>8.42</bold></td></tr></tbody></table></table-wrap></sec><sec id="sec2.4"><title>Studies of the Mechanism of Cell Death</title><p>Apoptosis, a
&#x0201c;clean&#x0201d; form of cell death that does not trigger an
inflammatory response, is particularly desirable in anticancer treatments
as apoptotic cells undergo orderly destruction while preserving cell
membrane integrity. To investigate whether our compounds induce apoptosis
or other types of cell death, we conducted MTT assays on two cell
lines: HCT116 WT and HCT116 double knockout (DKO), with the latter
being a human colorectal carcinoma strain resistant to mitochondrial
apoptosis. By comparing the IC<sub>50</sub> values in these two lines,
we aimed to determine the mechanism of action of our compounds (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>).</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>IC<sub>5O</sub> Values for Complexes <bold>1&#x02013;3</bold> in the
HCT116 WT an DKO Cancer Cells Measured at
24 h (&#x003bc;M)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center" char="&#x000b1;">HCT WT</th><th style="border:none;" align="center" char="&#x000b1;">HCT DKO</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>1a</bold></td><td style="border:none;" align="char" char="&#x000b1;">2.45&#x000a0;&#x000b1;&#x000a0;0.07</td><td style="border:none;" align="char" char="&#x000b1;">3.7&#x000a0;&#x000b1;&#x000a0;1.0</td></tr><tr><td style="border:none;" align="left"><bold>1c</bold></td><td style="border:none;" align="char" char="&#x000b1;">9.6&#x000a0;&#x000b1;&#x000a0;1.7</td><td style="border:none;" align="char" char="&#x000b1;">13.4&#x000a0;&#x000b1;&#x000a0;1.2</td></tr><tr><td style="border:none;" align="left"><bold>1d</bold></td><td style="border:none;" align="char" char="&#x000b1;">2.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="char" char="&#x000b1;">2.9&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td style="border:none;" align="left"><bold>2a</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.61&#x000a0;&#x000b1;&#x000a0;0.11</td><td style="border:none;" align="char" char="&#x000b1;">1.5&#x000a0;&#x000b1;&#x000a0;0.2</td></tr><tr><td style="border:none;" align="left"><bold>2b</bold></td><td style="border:none;" align="char" char="&#x000b1;">1.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="char" char="&#x000b1;">0.58&#x000a0;&#x000b1;&#x000a0;0.06</td></tr><tr><td style="border:none;" align="left"><bold>3a</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.95&#x000a0;&#x000b1;&#x000a0;0.14</td><td style="border:none;" align="char" char="&#x000b1;">3.0&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td style="border:none;" align="left"><bold>3b</bold></td><td style="border:none;" align="char" char="&#x000b1;">4.22&#x000a0;&#x000b1;&#x000a0;0.25</td><td style="border:none;" align="char" char="&#x000b1;">4.5&#x000a0;&#x000b1;&#x000a0;0.8</td></tr><tr><td style="border:none;" align="left"><bold>3c</bold></td><td style="border:none;" align="char" char="&#x000b1;">2.7&#x000a0;&#x000b1;&#x000a0;0.30</td><td style="border:none;" align="char" char="&#x000b1;">5.9&#x000a0;&#x000b1;&#x000a0;0.9</td></tr><tr><td style="border:none;" align="left"><bold>3d</bold></td><td style="border:none;" align="char" char="&#x000b1;">1.09&#x000a0;&#x000b1;&#x000a0;0.03</td><td style="border:none;" align="char" char="&#x000b1;">1.59&#x000a0;&#x000b1;&#x000a0;0.13</td></tr></tbody></table></table-wrap><p>The results presented
below show relatively similar IC<sub>50</sub> values for HCT116 WT
and DKO cells, suggesting that our compounds
act through pathways other than apoptosis. IC<sub>50</sub> values
for the DKO line are generally slightly higher than those for the
WT line, although the difference is minor. This suggests that while
our compounds may activate apoptosis, they also likely trigger alternative
cell death mechanisms independent of the Bax and Bak proteins, given
the typically high resistance of HCT116 DKO cells to apoptotic pathways.</p><p>To gain deeper insights into the type of cell death induced by
the gold(I) complexes, we conducted a flow cytometry analysis. This
approach allowed us to specifically detect apoptosis by examining
the rearrangement of membrane phospholipids that occurs at the onset
of apoptosis. During this process, phosphatidylserine (PS), normally
located on the inner membrane surface, translocates to the outer membrane,
exposing it to the external environment. To identify apoptotic cells,
Annexin V, a protein with a high affinity for PS, which binds selectively
to cells displaying PS on their outer membrane in a calcium-dependent
manner, was used. Annexin V was conjugated with a fluorochrome (DY-634),
allowing us to accurately quantify the degree of apoptosis within
the cell population through fluorescence detection.</p><p>The study
was conducted with two different concentrations of 10
and 20 &#x003bc;M (high concentrations were used to ensure significant
cell death rather than merely inhibiting cell growth) on the Jurkat
cell line and on Jurkat shBak, a strain resistant to mitochondrial
apoptosis (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>).</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Flow cytometry studies on complex <bold>2a</bold> in Jurkat Vector
and Jurkat shBak at 10 &#x003bc;M and 20 &#x003bc;M.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0005" id="gr8" position="float"/></fig><p>Observing the graphs, we could conclude that at
low doses, the
Jurkat shBak cell line is somehow protected compared to the Jurkat
vector line, which means that cell death is probably due to mitochondrial
apoptosis. However, at high doses, there are hardly any differences,
which would mean that other mechanisms of cell death are activated
at high concentrations.</p><p>To confirm further these findings, we
conducted flow cytometry
experiments with and without caspase inhibitor z-VAD-fmk (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). Caspases are crucial
enzymes in the apoptosis pathway, so a reduction in apoptosis in the
presence of this inhibitor would indicate that cell death is mediated
by caspase-dependent apoptosis. The results were striking as in the
control group cells maintained a uniform size, but upon treatment
with compound <bold>2a</bold>, cell size dramatically decreased, signaling
cell death. At lower concentrations, the caspase inhibitor z-VAD-fmk
significantly protected cells from apoptosis, as indicated by most
cells falling outside the positive zone. However, at higher concentrations,
this protective effect diminished.</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Flow cytometry studies on complex <bold>2a</bold> in Jurkat and
Jurkat + z-VAD-fmk at 10 &#x003bc;M and 20 &#x003bc;M.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0006" id="gr9" position="float"/></fig><p>The graphics presented in <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref> illustrate the conclusions drawn from these
two studies.
First, in Jurkat and Jurkat shBak cells, it is evident that at high
doses, there are minimal differences between the two cell lines. This
suggests that other mechanisms of cell death are activated at higher
concentrations. Jurkat shBak shows protective effects at concentrations
lower than 20 &#x003bc;M, but this protective effect diminishes at higher
concentrations, as reflected in the decreasing gap between the two
graphs (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>A).
Second, <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>B further
highlights this trend, demonstrating a pronounced difference between
the control and z-VAD-fmk curves at low concentrations. However, this
difference narrows at higher concentrations. These findings indicate
that at low concentrations, cell death is predominantly driven by
caspase-dependent mitochondrial apoptosis, whereas at higher concentrations,
alternative cell death pathways become active.</p><fig id="fig7" position="float"><label>Figure 7</label><caption><p>Graphics for the flow
cytometry studies on complex <bold>2a</bold> at different concentrations:
(a) Jurkat Vector and Jurkat shBak
and (b) Jurkat and Jurkat + z-VAD-fmk.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0007" id="gr10" position="float"/></fig><p>A similar study was performed for the thiolate
complex <bold>3d</bold> obtaining similar results. In this case, the
difference between
the cell lines Jurkat and Jurkat shBak was not significant, and the
same observation occurred in the presence of z-VAD-fmk, indicating
that cell death was caused by apoptosis but is independent of caspase.
The data can be found in the Supporting Information (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">Figures S43&#x02013;S45</ext-link>).</p></sec><sec id="sec2.5"><title>Flow Cytometry Studies</title><sec id="sec2.5.1"><title>Cell
Cycle Arrest Studies and Cell Death</title><p>The cell cycle
is divided into two primary phases: mitosis (M), where cell division
occurs, and interphase, which encompasses the G1 (pre-DNA synthesis),
S (DNA synthesis), and G2 (predivision) stages. After interphase,
cells may enter the G0 phase, a state where they are not actively
cycling but maintain the potential for division. The G0 phase mostly
includes nongrowing or nonproliferating cells, which can revert to
the G1 phase in response to proliferation signals or other mitogenic
stimuli. The progression of the cell cycle is regulated by CDK-mediated
phosphorylation, protein degradation via the ubiquitin&#x02013;proteasome
system, and checkpoints at crucial transitions (G1-S and G2-M) to
ensure genomic integrity. The p53 gene plays a pivotal role in halting
the cycle by inhibiting cyclins and is closely linked to apoptosis
following cycle arrest. Investigating the cell cycle is vital for
understanding drug mechanisms. Techniques such as flow cytometry,
which measures DNA content, are used to analyze the distribution of
cells across different cycle phases. Thus, A549 cells were treated
with compound <bold>3b</bold> for 24 h to study its effects on both
in the cell cycle and in the type of cell death (<xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref>).</p><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Cell Cycle
and Type of Cell Death
Induced by Compound <bold>3b</bold> after 24 h of Incubation</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">cell cycle</th><th style="border:none;" align="center" char=".">G0G1</th><th style="border:none;" align="center" char=".">S</th><th style="border:none;" align="center" char=".">G2M</th></tr></thead><tbody><tr><td style="border:none;" align="left">control</td><td style="border:none;" align="char" char=".">58.82</td><td style="border:none;" align="char" char=".">28.73</td><td style="border:none;" align="char" char=".">12.44</td></tr><tr><td style="border:none;" align="left"><bold>3b</bold></td><td style="border:none;" align="char" char=".">82.85</td><td style="border:none;" align="char" char=".">8.60</td><td style="border:none;" align="char" char=".">8.55</td></tr></tbody></table><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">cell death</th><th style="border:none;" align="center" char=".">intact (A3)</th><th style="border:none;" align="center" char=".">L-AP<xref rid="t4fn1" ref-type="table-fn">a</xref>(A2)</th><th style="border:none;" align="center" char=".">E-AP<xref rid="t4fn1" ref-type="table-fn">a</xref> (A4)</th><th style="border:none;" align="center" char=".">N<xref rid="t4fn1" ref-type="table-fn">a</xref> (A1)</th></tr></thead><tbody><tr><td style="border:none;" align="left">control</td><td style="border:none;" align="char" char=".">70.57</td><td style="border:none;" align="char" char=".">27.88</td><td style="border:none;" align="char" char=".">0.58</td><td style="border:none;" align="char" char=".">0.97</td></tr><tr><td style="border:none;" align="left"><bold>3b</bold></td><td style="border:none;" align="char" char=".">25.73</td><td style="border:none;" align="char" char=".">59.65</td><td style="border:none;" align="char" char=".">11.20</td><td style="border:none;" align="char" char=".">3.42</td></tr></tbody></table><table-wrap-foot><fn id="t4fn1"><label>a</label><p>E-AP: early apoptosis,
L-AP: late
apoptosis, N: necrosis.</p></fn></table-wrap-foot></table-wrap><p>As shown in <xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">Figures S46&#x02013;S48</ext-link>, the presence
of compound <bold>3b</bold> significantly increased the number of
cells in the G0/G1 phase and decreased S and G2/M phases compared
to the control. These data suggest that G0/G1 phase arrest may be
responsible for the antiproliferative effects of compounds <bold>3b</bold> on A549 cells. Arrest in the G0/G1 phase can result from severe
and irreparable DNA damage, preventing the cell from entering the
S phase. In addition, <bold>3b</bold> preferentially promotes cell
death by triggering apoptosis.</p></sec><sec id="sec2.5.2"><title>ROS Production and Mitochondrial
Membrane Potential</title><p>Redox homeostasis is crucial for sustaining
cellular processes, and
its disruption can lead to an increase in the level of reactive oxygen
species (ROS). Elevated ROS levels cause oxidative stress, which can
damage proteins and DNA, ultimately triggering cell death. This process
is often associated with programmed cell death mechanisms, such as
apoptosis or autophagy. Mitochondria play a central role in regulating
both cell survival and death. As critical hubs of metabolic activity,
they are implicated in various diseases and have become a major therapeutic
target, especially in cancer treatment. Mitochondrial membrane potential
(&#x00394;&#x003a8;), maintained by ion concentration gradients, is a
key indicator of mitochondrial function. Disruption in energy metabolism
reduces &#x00394;&#x003a8;, signaling mitochondrial damage. Therefore,
the ability of compound <bold>3b</bold> to generate ROS and mitochondrial
membrane depolarization was evaluated. <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref> (top) illustrates a slight increase in the
reactive oxygen species, as indicated by the enhanced luminescence
intensity. This shift appears to the right, with the control shown
in red and <bold>3b</bold> in blue. Additionally, a mild decrease
in the mitochondrial membrane potential is observed (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>, bottom). In the control group,
10.14% of the mitochondrial membrane potential is disrupted, whereas,
in the presence of complex <bold>3b</bold>, this disruption increases
to 14.22%. These effects were observed after incubating A549 cells
with <bold>3b</bold> for 24 h.</p><fig id="fig8" position="float"><label>Figure 8</label><caption><p>ROS and &#x00394;&#x003a8; of complex <bold>3b</bold> in A549 cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0008" id="gr11" position="float"/></fig></sec></sec><sec id="sec2.6"><title>DNA Interaction</title><p>The interaction of the bis(carbenes)
(<bold>2a</bold> and <bold>2b</bold>) with DNA was studied due to
their potentially more planar structure, which has been associated
with DNA intercalation. These compounds might enable DNA intercalation.
Absorption spectral titration experiments were performed according
to the methodology described in our previous works.<sup><xref ref-type="bibr" rid="ref44">44</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup></p><p><xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref> presents
the UV&#x02013;vis spectra obtained by gradually adding increasing
amounts of DNA to a solution of <bold>2a</bold> or <bold>2b</bold> (100 &#x003bc;M), along with data extracted from the absorption spectral
titration experiments. As shown in <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>, compound <bold>2a</bold> exhibits minimal
interaction with DNA, resulting in negligible changes in the absorption
spectra. Consequently, this minimal interaction precluded calculation
of the DNA-binding constant (<italic>K</italic><sub>b</sub>). In contrast,
compound <bold>2b</bold> exhibits a clear decrease in band intensity
with increasing DNA concentration, indicating that it interacts with
DNA via intercalation. The calculated binding constant (<italic>K</italic><sub>b</sub> = 4.48 &#x000d7; 10<sup>4</sup>) suggests that <bold>2b</bold> is a moderate intercalator. These results align with the structural
characteristics of these compounds. For compound <bold>2b</bold>,
the presence of pyridine rings enhances its planarity, unlike compound <bold>2a</bold>, where the higher number of cyclohexyl rings reduces planarity.</p><fig id="fig9" position="float"><label>Figure 9</label><caption><p>Absorption
spectral titration experiments for complexes <bold>2a</bold> and <bold>2b</bold>. The arrow indicates that the absorbance of
the complex decreases with the addition of CT-DNA.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0009" id="gr12" position="float"/></fig></sec><sec id="sec2.7"><title>Inhibition Studies of TrxR in A549 Cell Lysates</title><p>Thioredoxin
Reductase (TrxR) is a critical biological target of gold(I) complexes.
Therefore, the ability of the selected compounds (<bold>2b</bold>, <bold>3b</bold>, and <bold>3d</bold>), along with auranofin as a reference,
to inhibit the TrxR system was evaluated using an insulin reduction
assay. This assay is well established for assessing enzyme inhibition.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> The thioredoxin reductase system is known to
efficiently reduce insulin interchain disulfide bridges, making insulin
an ideal substrate for this analysis. Additionally, the reaction can
be monitored using DTNB, which reacts with free thiol groups of insulin
to generate TNB, which is a yellow compound. This allows the inhibition
of TrxR to be quantified by UV&#x02013;vis spectroscopy (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>).</p><fig id="fig10" position="float"><label>Figure 10</label><caption><p>Insulin reduction assay.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_0010" id="gr13" position="float"/></fig><p>The inhibition assay was conducted using the A549
cell line, which
overexpresses TrxR.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> Both the selected
compounds and auranofin were tested at a concentration of 3 &#x003bc;M.
The results are presented in <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>.</p><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><title>Inhibition Studies of Thioredoxin
Reductase Activity (%)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/></colgroup><thead><tr><th style="border:none;" align="center">compound</th><th style="border:none;" align="center" char="&#x000b1;">inhibition of TrxR&#x000a0;%</th></tr></thead><tbody><tr><td style="border:none;" align="left">auranofin</td><td style="border:none;" align="char" char="&#x000b1;">85&#x000a0;&#x000b1;&#x000a0;3</td></tr><tr><td style="border:none;" align="left"><bold>2b</bold></td><td style="border:none;" align="char" char="&#x000b1;">73&#x000a0;&#x000b1;&#x000a0;2</td></tr><tr><td style="border:none;" align="left"><bold>3b</bold></td><td style="border:none;" align="char" char="&#x000b1;">51&#x000a0;&#x000b1;&#x000a0;5</td></tr><tr><td style="border:none;" align="left"><bold>3d</bold></td><td style="border:none;" align="char" char="&#x000b1;">44&#x000a0;&#x000b1;&#x000a0;5</td></tr></tbody></table></table-wrap><p>The results of this study
indicate that complex <bold>2b</bold>, a bis(carbene) compound, exhibits
inhibition levels comparable
to those of auranofin at the same concentration. In contrast, complexes <bold>3b</bold> and <bold>3d</bold>, which feature thiolate as the auxiliary
ligand, demonstrate lower inhibition than auranofin, with approximately
half of the inhibitory effect at this concentration. It is important
to highlight that the results obtained in this study are highly significant,
as all the evaluated compounds have demonstrated potent inhibition
of the TrxR system in cell lysates. Notably, compound <bold>2b</bold> stands out, with an inhibition comparable to that of auranofin,
which is one of the most potent and selective TrxR inhibitors known
to date. Furthermore, it is important to highlight that, to date,
Au-ADC compounds have demonstrated poor inhibition of the TrxR system.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup></p></sec></sec><sec id="sec3"><title>Conclusions</title><p>In this study, the successful
synthesis and evaluation of the anticancer
properties of a novel series of gold(I) ADC complexes have been accomplished,
significantly advancing the underexplored potential of these compounds
in biological systems. Although such gold complexes are well established
in catalysis and materials science, this work highlights their transformative
potential in anticancer therapeutics. Through the nucleophilic addition
of various amines to isocyanide [AuCl(CNCy)] complexes, three distinct
families of compounds were developed based on their auxiliary ligands:
gold-chloride ADC complexes (featuring chiral and achiral substituents),
bis(carbene) complexes, and thiolate-gold ADC complexes. Comprehensive
characterization via NMR, IR, HRMS, and X-ray crystallography (for
compounds <bold>1a</bold>, <bold>1b</bold>, and <bold>3c</bold>) validated
their structures.</p><p>The findings indicate that ligand design critically
determines
the cytotoxic efficacy of gold(I) ADC complexes. Among the tested
compounds, gold-chloride derivatives exhibited selective cytotoxicity,
with <bold>1a</bold> and <bold>1b</bold> showing leukemia-specific
potency and <bold>1a</bold> being more active in general. Chiral derivatives
like <bold>1c</bold> exhibited targeted effects against lung and pancreatic
cancers and <bold>1d</bold> toward colon cancer. Bis(carbene) complexes
(<bold>2a</bold> and <bold>2b</bold>) displayed remarkable cytotoxicity,
likely enhanced by their cationic nature, which facilitates cellular
uptake. Remarkably, the gold(I) thiolate-carbenes emerged as the most
potent subgroup, achieving submicromolar IC<sub>50</sub> values, with
compound <bold>3b</bold> attaining a selectivity index (SI) of 73.68
compared to healthy cells.</p><p>Mechanistic studies revealed that
these complexes preferentially
induce apoptosis at low concentrations, while high concentrations
trigger alternative cell death pathways. Cell cycle analysis showed
that <bold>3b</bold> arrested cells in the G0/G1 phase, indicating
severe DNA damage. Interestingly, bis(carbene) complexes <bold>2</bold> exhibit DNA-binding properties, with <bold>2b</bold> bearing two
pyridyl substituents showing the highest constant. Additionally, compound <bold>3b</bold> moderately increased the level of ROS generation and mitochondrial
membrane depolarization. TrxR inhibition studies identified <bold>2b</bold>, <bold>3b</bold>, and <bold>3d</bold> as potent inhibitors,
with <bold>2b</bold> matching the potency of auranofin, which is one
of the best TrxR inhibitors.</p><p>In conclusion, the synthesized
gold ADC complexes represent a significant
advancement in the development of chemotherapeutic agents, combining
high selectivity with potent cytotoxic activity against resistant
cancer cell lines. Their multitarget mechanisms, including ROS generation,
mitochondrial damage, DNA binding, and TrxR inhibition, highlight
their versatility in disrupting cancer cell survival. These findings
not only underscore the therapeutic potential of gold ADC complexes
but also pave the way for further exploration of their structure&#x02013;activity
relationships and optimization as effective anticancer agents.</p></sec><sec id="sec4"><title>Experimental Section</title><sec id="sec4.1"><title>Synthesis and Characterization</title><sec id="sec4.1.1"><title>General
Procedure for the Synthesis of <bold>1a&#x02013;1d</bold></title><p>To a solution of [AuCl(CNCy)] in dichloromethane (25 mL)
was added 1 equiv of the corresponding amine: (<italic>N</italic>-(pyridylmethyl)cyclohexane)
(<bold>1a</bold>), di(2-picolyl)amine (<bold>1b</bold>), (1<italic>R</italic>,2<italic>S</italic>)-(+)-<italic>cis</italic>-1-amino-2-indanol
(<bold>1c</bold>), (1<italic>R</italic>,2<italic>R</italic>)-(&#x02212;)-<italic>N</italic>-<italic>p</italic>-tosyl-1,2-cyclohexanediamine (<bold>1d</bold>), and the mixture was stirred at room temperature during
24 h, The solvent was removed under vacuo to 5 mL and <italic>n</italic>-hexane was used to precipitate the solid. After filtration, compounds <bold>1a&#x02013;1d</bold> were obtained.</p><p><bold>1a</bold>: [AuCl(CNCy)]
0.1024 g (0.3 mmol) and <italic>N</italic>-(pyridylmethyl)cyclohexane
0.0570 g (0.3 mmol). Yield = 78%. <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) &#x003b4;: 8.79 (s, NH), 8.51 (d, CH<sub>Ar,2</sub>), 7.76 (t, CH<sub>Ar,4</sub>), 7.36 (d, CH<sub>Ar,5</sub>), 7.28
(t, CH<sub>Ar,3</sub>), 4.86&#x02013;4.74 (m, H<sub>cy</sub>), 4.14&#x02013;4.05
(m, CH<sub>cy</sub>), 2.03&#x02013;1.02 (m, CH<sub>2</sub>,<sub>cy</sub>). <sup>13</sup>C{<sup>1</sup>H}-APT NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz) &#x003b4;: 192.8 (s, C<sub>carbene</sub>), 156.5 (s, C<sub>ipso,py</sub>), 149.0 (s, CH<sub>py</sub>), 138.4 (s, CH<sub>py</sub>), 123.8 (s, CH<sub>py</sub>), 123.7 (s, CH<sub>py</sub>), 69.6 (s,
CH<sub>cy</sub>), 59.9 (s, CH<sub>cy</sub>), 51.0 (s, CH<sub>2</sub>), 34.4 (s, CH<sub>2,cy</sub>), 32.8 (s, CH<sub>2,cy</sub>), 26.3
(s, CH<sub>2,cy</sub>), 25.9 (s, CH<sub>2,cy</sub>), 24.9 (s, CH<sub>2,cy</sub>). Elemental analysis (%): C<sub>19</sub>H<sub>29</sub>AuClN<sub>3</sub> requires: C 42.91, H 5.50, N 7.90; found: C 43.14,
H 5.35, N 7.69. HRMS (ESI-QTOF) <italic>m</italic>/<italic>z</italic> (%): Calculated for C<sub>19</sub>H<sub>29</sub>AuClN<sub>3</sub>Na, 554.1608; found, 554.1604 [M + Na]<sup>+</sup>. IR: &#x003bd; (C=N):
1587 cm<sup>&#x02013;1</sup>, &#x003bd; (NH): 2932 cm<sup>&#x02013;1</sup>, &#x003bd; (Au&#x02013;Cl): 325 cm<sup>&#x02013;1</sup>.</p><p><bold>1b</bold>: [AuCl(CNCy)] 0.1024 g (0.3 mmol) and di(2-picolyl)amine
0.0598 g (0.3 mmol). Yield = 50%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4;: 9.16 (m, 1H, NH), 8.57 (d, 1H, <italic>J</italic> = 4.2 Hz, H-6), 8.48 (d, 1H, <italic>J</italic> = 4.1 Hz, H-6&#x02032;),
7.60 (m, 4H, H-3, H-3&#x02032;, H-4, H-4&#x02032;), 7.25 (m, 2H, H-5,
H-5&#x02032;), 7.00 (d, 1H, <italic>J</italic> = 7.7 Hz, H-3 o H-3&#x02032;),
5.35 (s, 2H, CH<sub>2</sub>), 4.55 (s, 2H, CH<sub>2</sub>), 4.22 (m,
1H, CH<sub>cy</sub>), 2.02 (m, 2H, cy), 1.69 (m, 3H, cy), 1.43 (m,
4H, cy), 1.26 (m, 1H, cy). <sup>13</sup>C{<sup>1</sup>H}-APT NMR (CDCl<sub>3</sub>, 101 MHz) &#x003b4;: 193.0 (s, 1C, C=N), 156.5 and 154.8
(s, 2C, C-2, C-2&#x02032;), 149.4 and 148.6 (s, 2C, C-6, C-6&#x02032;),
137.9 and 137.2 (s, 2C, C-4, C-4&#x02032;), 124.0 and 123.2 (s, 2C,
C-3, C-3&#x02032;), 123.6 and 123.7 (s, 2C, C-5, C-5&#x02032;), 64.8
(s, 1C, CH<sub>2</sub>), 59.2 (s, 1C, CH<sub>cy</sub>), 55.3 (s, 1C,
CH<sub>2</sub>), 34.0 (s, 2C, cy), 25.4 (s, 1C, cy), 24.4 (s, 2C,
cy). Elemental analysis (%): C<sub>19</sub>H<sub>24</sub>AuClN<sub>4</sub> requires: C 42.19, H 4.47, N 10.36; found: C 42.27, H 4.68,
N 10.51. HRMS (ESI<sup>+</sup>) <italic>m</italic>/<italic>z</italic> %: Calculated for C<sub>19</sub>H<sub>25</sub>AuN<sub>4</sub>, 506.1739;
found, 506.1800 [M &#x02013; Cl]<sup>+</sup>.</p><p><bold>1c</bold>: [AuCl(CNCy)] 0.0683 g (0.2 mmol) and (1<italic>R</italic>,2<italic>S</italic>)-(+)-<italic>cis</italic>-1-amino-2-indanol
0.0299 g (0.2 mmol). Yield = 59%. <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) &#x003b4;: 7.32&#x02013;7.22 (m, CH<sub>Ar</sub>), 4.31 (m, CH<sub>2,Ar</sub>), 3.96&#x02013;3.87 (m, CH<sub>2cy</sub>), 3.05 (m, CHNH), 2.82 (m, CHOH), 2.85 (s, OH), 2.22&#x02013;1.90
(s, CH<sub>2,cy</sub>), 1.86&#x02013;1.66 (s, CH<sub>2,cy</sub>), 1.53&#x02013;1.36
(s, CH<sub>2,cy</sub>). <sup>13</sup>C{<sup>1</sup>H}-APT NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz) &#x003b4;: 128.3 (s, CH<sub>Ar</sub>), 127.3 (s, CH<sub>Ar</sub>), 125.8 (s, CH<sub>Ar</sub>), 124.4
(s, CH<sub>Ar</sub>), 73.3 (s, CHOH), 59.3 (s, CHNH), 55.6 (s, CH<sub>ipso</sub>), 39.9 (s, CH<sub>2cy</sub>), 32.1 (s, CH<sub>2,cy</sub>), 25.1 (s, CH<sub>2,cy</sub>), 23.2 (s, CH<sub>2,cy</sub>). Elemental
analysis (%): C<sub>16</sub>H<sub>22</sub>AuClN<sub>2</sub>O requires:
C 39.16, H 4.52, N 5.71; found: C 38.89, H 4.34, N 5.89. HRMS (ESI-QTOF) <italic>m</italic>/<italic>z</italic> (%): Calculated for C<sub>16</sub>H<sub>22</sub>AuN<sub>2</sub>O, 455.1392; found, 455.1391 [M &#x02013; Cl]<sup>+</sup>. IR: &#x003bd; (C=N): 1567 cm<sup>&#x02013;1</sup>, &#x003bd;
(NH): 3314, 2933 cm<sup>&#x02013;1</sup>, &#x003bd; (Au&#x02013;Cl): 310
cm<sup>&#x02013;1</sup>.</p><p><bold>1d</bold>: [AuCl(CNCy)] 0.0683
g (0.2 mmol) and (1<italic>R</italic>,2<italic>R</italic>)-(&#x02212;)-<italic>N</italic>-<italic>p</italic>-tosyl-1,2-cyclohexanediamine 0.0537
g (0.2 mmol). Yield
= 68%. <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) &#x003b4;:
7.89&#x02013;7.83 (m, rotamer A, Ph), 7.77&#x02013;7.70 (m, rotamer
B, rotamer C, Ph), 7.38&#x02013;7.28 (m, rotamer A, rotamer B, rotamer
C, Ph), 4.00&#x02013;3.79 (m, CH<sub>cy</sub>), 3.47&#x02013;3.34 (m,
CH<sub>cy</sub>), 3.29&#x02013;3.00 (m, CH<sub>cy</sub>), 2.43 (s,
rotamer B or C, CH<sub>3</sub>), 2.42 (s, rotamer B or C, CH<sub>3</sub>), 2.41 (s, rotamer A, CH<sub>3</sub>), 2.30&#x02013;1.02 (m, CH<sub>2,cy</sub>). <sup>13</sup>C{<sup>1</sup>H}-APT NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz) &#x003b4;: 144.4 (s, Ph), 144.3 (s, Ph), 139.0
(s, Ph), 138.8 (s, Ph), 138.5 (s, Ph), 130.4 (s, Ph), 130.3 (s, Ph),
127.5 (s, Ph), 127.3 (s, Ph), 127.1 (s, Ph), 64.1 (s, CH), 63.8 (s,
CH), 59.4 (s, CH), 57.8 (s, CH), 57.4 (s, CH), 57.3 (s, CH), 54.9
(s, CH), 52.0 (s, CH), 35.3 (m, CH<sub>2,cy</sub>), 34.6 (m, CH<sub>2,cy</sub>), 34.5 (m, CH<sub>2,cy</sub>), 33.1 (m, CH<sub>2,cy</sub>), 32.5 (m, CH<sub>2,cy</sub>), 32.1 (m, CH<sub>2,cy</sub>), 31.8
(m, CH<sub>2,cy</sub>), 25.8 (m, CH<sub>2,cy</sub>), 25.7 (m, CH<sub>2,cy</sub>), 25.6 (m, CH<sub>2,cy</sub>), 25.4 (m, CH<sub>2,cy</sub>), 25.3 (m, CH<sub>2,cy</sub>), 25.1 (m, CH<sub>2,cy</sub>), 25.0
(m, CH<sub>2,cy</sub>), 24.8 (m, CH<sub>2,cy</sub>), 24.7 (m, CH<sub>2,cy</sub>), 24.5 (m, CH<sub>2,cy</sub>), 21.8 (s, 1C, CH<sub>3</sub>). Elemental analysis (%): C<sub>20</sub>H<sub>31</sub>AuClN<sub>3</sub>O<sub>2</sub>S requires: C 39.38, H 5.12, N 6.89, S 5.26;
found: C 39.51, H 5.31, N 6.97, S 5.08. HRMS (ESI-QTOF) <italic>m</italic>/<italic>z</italic> (%): Calculated for C<sub>20</sub>H<sub>31</sub>AuN<sub>3</sub>O<sub>2</sub>S, 574.1797; found, 574.1829 [M &#x02013;
Cl]<sup>+</sup>. IR: &#x003bd; (NH): 3084, 2926, 2855 cm<sup>&#x02013;1</sup>, &#x003bd; (Au&#x02013;Cl): 312 cm<sup>&#x02013;1</sup>.</p></sec><sec id="sec4.1.2"><title>General Procedure
for the Synthesis of <bold>2a</bold> and <bold>2b</bold></title><p>To a solution of [(CNCy)Au(CNCy)]OTf 0.2070 g
(0.5 mmol) in dichloromethane (25 mL) was added 2 equiv of the corresponding
amine: di(2-picolyl)amine (0.2000 g, 1.0 mmol) (<bold>2a</bold>) and
(<italic>N</italic>-(pyridylmethyl)cyclohexane) (0.1903 g, 1.0 mmol)
(<bold>2b</bold>), and the mixture was stirred at room temperature
during 7 h. The solvent was removed in vacuo to 5 mL and compounds <bold>2a</bold> and <bold>2b</bold> were obtained, after filtration, using <italic>n</italic>-hexane as a precipitating agent.</p><p><bold>2a</bold>: Yield = 68%. <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400
MHz) &#x003b4;: 9.51 (s, NH), 8.49 (d, CH<sub>Ar,2</sub>), 8.47 (d,
CH<sub>Ar,2&#x02032;</sub>), 7.64 (t, CH<sub>Ar,4</sub>), 7.59 (t,
CH<sub>Ar,4&#x02032;</sub>), 7.26 (d, CH<sub>Ar,3</sub>), 7.19 (d,
CH<sub>Ar,3&#x02032;</sub>), 7.17 (d, CH<sub>Ar,3&#x02032;</sub>), 6.69
(t, CH<sub>Ar,5</sub>), 5.15 (s, CH<sub>2</sub>), 4.47 (s, CH<sub>2</sub>), 4.00&#x02013;3.86 (m, H<sub>cy</sub>), 1.97&#x02013;1.16
(m, CH<sub>2,cy</sub>). <sup>13</sup>C{<sup>1</sup>H}-APT NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz) &#x003b4;: 206.1 (s, C<sub>carbene</sub>), 156.3 (s, C<sub>ipso,py</sub>), 154.9 (s, C<sub>ipso,py</sub>),
150.2 (s, CH<sub>py</sub>), 148.9 (s, CH<sub>py</sub>), 138.4 (s,
CH<sub>py</sub>), 137.4 (s, CH<sub>py</sub>), 124.5 (s, CH<sub>py</sub>), 124.1 (s, CH<sub>py</sub>), 123.6 (s, CH<sub>py</sub>), 122.3
(s, CH<sub>py</sub>), 63.9 (s, CH<sub>2</sub>), 59.0 (s, CH<sub>cy</sub>), 56.3 (s, CH<sub>2</sub>), 34.6 (s, CH<sub>2,cy</sub>), 25.6 (s,
CH<sub>2,cy</sub>), 24.9 (s, CH<sub>2,cy</sub>). Elemental analysis
(%): C<sub>39</sub>H<sub>58</sub>AuF<sub>3</sub>N<sub>6</sub>O<sub>3</sub>S requires: C 49.57, H 6.19, N 8.89, S 3.39; found: C 49.74,
H 6.36, N 8.71, S 3.57. HRMS (ESI-QTOF) <italic>m</italic>/<italic>z</italic> (%): Calculated for C<sub>38</sub>H<sub>58</sub>AuN<sub>6</sub>, 795.4383; found, 795.4414 [M-OTf]<sup>+</sup>. IR: &#x003bd;
(C=N): 1547 cm<sup>&#x02013;1</sup>, &#x003bd; (NH): 2987 cm<sup>&#x02013;1</sup>, &#x003bd; (OTf): 1258, 1224, 1136, and 1029 cm<sup>&#x02013;1</sup>.</p><p><bold>2b</bold>: Yield = 81%. <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) &#x003b4;: 9.51 (s, NH),
8.53 (d, CH<sub>Ar,2</sub>), 7.80 (t, CH<sub>Ar,4</sub>), 7.42 (d,
CH<sub>Ar,5</sub>), 7.33
(t, CH<sub>Ar,3</sub>), 4.57&#x02013;4.51 (m, CH<sub>cy</sub>), 4.45
(s, CH<sub>2</sub>), 4.04&#x02013;3.09 (m, CH<sub>cy</sub>), 2.07&#x02013;1.09
(m, CH<sub>2,cy</sub>). <sup>13</sup>C-APT NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz) &#x003b4;: 205.2 (s, C<sub>carbene</sub>), 156.3
(s, C<sub>ipso,py</sub>), 149.0 (s, CH<sub>py</sub>), 138.7 (s, CH<sub>py</sub>), 123.4 (s, CH<sub>py</sub>), 124.0 (s, CH<sub>py</sub>),
69.1 (s, CH<sub>cy</sub>), 59.3 (s, CH<sub>cy</sub>), 51.4 (s, CH<sub>2</sub>), 34.8 (s, CH<sub>2,cy</sub>), 32.8 (s, CH<sub>2,cy</sub>), 26.4 (s, CH<sub>2,cy</sub>), 25.7 (s, CH<sub>2,cy</sub>), 25.1
(s, CH<sub>2,cy</sub>). Elemental analysis (%): C<sub>39</sub>H<sub>49</sub>AuF<sub>3</sub>N<sub>8</sub>O<sub>3</sub>S requires: C 48.59,
H 5.12, N 11.62, S 3.33; found: C 48.79, H 5.31, N 11.91, S 3.23.
HRMS (ESI-QTOF) <italic>m</italic>/<italic>z</italic> (%): Calculated
for C<sub>38</sub>H<sub>49</sub>AuN<sub>8</sub>, 814.3740; found,
814.3766. [M-OTf]<sup>+</sup>. IR: &#x003bd; (C=N): 1588 cm<sup>&#x02013;1</sup>, &#x003bd; (NH): 2927 cm<sup>&#x02013;1</sup>, &#x003bd;
(OTf): 1266, 1219, and 1030 cm<sup>&#x02013;1</sup>.</p></sec><sec id="sec4.1.3"><title>General Procedure
for the Synthesis of <bold>3a&#x02013;3d</bold></title><p>To a solution
of complex <bold>1a</bold> (0.0530 g) (0.1
mmol) in dichloromethane (25 mL) was added an excess of K<sub>2</sub>CO<sub>3</sub> (0.1400 g 1.5 mmol) and 1 equiv of the corresponding
thiolate: 2-thiocytosine (0.0128 g) (<bold>3a</bold>), 2-mercaptopyridine
(0.0111 g) (<bold>3b</bold>), 2-thiouracil (0.0128) (<bold>3c</bold>), and 1-thio-&#x003b2;-<sc>d</sc>-glucose (0.0364) (<bold>3d</bold>), and the mixture was stirred for 3 h. Subsequently, the reaction
was filtered over Celite, the solvent was removed under vacuo to 5
mL, and compounds <bold>3a&#x02013;3d</bold> were obtained, after filtration,
using <italic>n</italic>-hexane as a precipitating agent.</p><p><bold>3a</bold>: Yield = 65%. <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) &#x003b4;: 8.52 (d, CH<sub>py,2</sub>), 8.41 (s, NH), 7.85
(t, CH<sub>Ar,4&#x02032;</sub>), 7.76 (t, CH<sub>Ar,4</sub>), 7.37
(d, CH<sub>Ar,5</sub>), 7.26 (t, CH<sub>Ar,3</sub>), 6.00 (d, CH<sub>Ar,3&#x02032;</sub>), 5.00 (m, H<sub>cy</sub>),4.68 (s, NH), 4.44
(s, CH<sub>2</sub>), 4.26 (m, H<sub>cy</sub>), 2.10&#x02013;1.04 (m,
CH<sub>2</sub>,<sub>cy</sub>). <sup>13</sup>C{<sup>1</sup>H}-APT NMR
(CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz) &#x003b4;: 202.3 (s, C<sub>carbene</sub>), 162.5 (s, C<sub>ipso,py</sub>), 156.8 (s, C<sub>ipso</sub>), 155.9
(s, CH<sub>cytosine</sub>), 149.1 (s, CH<sub>py</sub>), 138.2 (s,
CH<sub>py</sub>), 123.6 (s, CH<sub>py</sub>), 123.6 (s, CH<sub>py</sub>), 99.9 (s, CH<sub>cytosine</sub>), 68.8 (s, CH<sub>cy</sub>), 59.2
(s, CH<sub>2</sub>), 50.8 (s, CH<sub>2</sub>), 34.6 (s, CH<sub>2,cy</sub>), 32.8 (s, CH<sub>2,cy</sub>), 30.2 (s, CH<sub>2,cy</sub>), 26.1
(s, CH<sub>2,cy</sub>), 25.9 (s, CH<sub>2,cy</sub>), 25.0 (s, CH<sub>2,cy</sub>). Elemental analysis (%): C<sub>23</sub>H<sub>33</sub>AuN<sub>6</sub>S requires: C 44.37, H 5.34, N 13.50, S 5.15; found:
C 44.52, H 5.28, N 13.71, S 4.99. HRMS (ESI-QTOF) <italic>m</italic>/<italic>z</italic> (%): calculated for C<sub>23</sub>H<sub>34</sub>AuN<sub>6</sub>S, 623.2226; found, 623.2260 [M + H]<sup>+</sup>.
IR: &#x003bd; (C=N): 1572 cm<sup>&#x02013;1</sup>, &#x003bd; (NH):
2987 and 2901 cm<sup>&#x02013;1</sup>, &#x003bd; (Au&#x02013;S): 404 cm<sup>&#x02013;1</sup>.</p><p><bold>3b</bold>: Yield = 61%. <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) &#x003b4;: 8.59 (s, NH),
8.51 (d, CH<sub>Ar,2</sub>), 8.17 (d, CH<sub>Ar,2&#x02032;</sub>),
7.75 (t, CH<sub>Ar,4</sub>), 7.50 (t, CH<sub>Ar,4&#x02032;</sub>),
7.38 (d, CH<sub>Ar,5</sub>), 7.28 (d, CH<sub>Ar,5&#x02032;</sub>),
7.17 (d, CH<sub>Ar,5&#x02032;</sub>), 6.77 (t, CH<sub>Ar,5</sub>),
5.00&#x02013;4.89 (m, H<sub>cy</sub>), 4.44 (s, CH<sub>2</sub>), 4.21&#x02013;4.17
(m, H<sub>cy</sub>),
2.03&#x02013;1.15 (m, CH<sub>2,cy</sub>). <sup>13</sup>C{<sup>1</sup>H}-APT NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz) &#x003b4;: 168.6
(s, C<sub>ipso,py</sub>), 156.7 (s, C<sub>ipso,py</sub>), 149.0 (s,
CH<sub>py</sub>), 138.4 (s, CH<sub>py</sub>), 135.0 (s, CH<sub>py</sub>), 127.2 (s, CH<sub>py</sub>), 123.7 (s, CH<sub>py</sub>), 123.6
(s, CH<sub>py</sub>), 117.8 (s, CH<sub>py</sub>), 68.8 (s, CH<sub>cy</sub>), 59.1 (s, CH<sub>cy</sub>), 50.9 (s, CH<sub>2</sub>), 34.5
(s, CH<sub>2,cy</sub>), 32.8 (s, CH<sub>2,cy</sub>), 36.2 (s, CH<sub>2,cy</sub>), 25.9 (s, CH<sub>2,cy</sub>), 25.0 (s, CH<sub>2,cy</sub>). Elemental analysis (%): C<sub>24</sub>H<sub>33</sub>AuN<sub>4</sub>S requires: C 47.52, H 5.48, N 9.24, S 5.29; found: C 47.39, H 5.61,
N 9.36, S 5.34. HRMS (ESI-QTOF) <italic>m</italic>/<italic>z</italic> (%): Calculated for C<sub>24</sub>H<sub>34</sub>AuN<sub>4</sub>S,
607.2164; found, 607.2175 [M + H]<sup>+</sup>. IR: &#x003bd; (C=N):
1571 cm<sup>&#x02013;1</sup>, &#x003bd; (NH): 2925 cm<sup>&#x02013;1</sup>, &#x003bd; (Au&#x02013;S): 402 cm<sup>&#x02013;1</sup>.</p><p><bold>3c</bold>: Yield = 58%. <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) &#x003b4;: 9.66 (s, NH), 8.87 (s, NH), 8.55
(d, CH<sub>Ar,2</sub>), 7.76 (t, CH<sub>Ar,4</sub>), 7.69 (d, CH<sub>Ar,2&#x02032;</sub>), 7.31 (t, CH<sub>Ar,5</sub>), 7.29 (d, CH<sub>Ar,3</sub>), 5.95 (d, CH<sub>Ar,3&#x02032;</sub>), 4.87&#x02013;4.76
(m, H<sub>cy</sub>), 4.44 (s, CH<sub>2</sub>), 4.16&#x02013;4.05 (m,
H<sub>cy</sub>), 2.00&#x02013;1.04 (m, CH<sub>2</sub>,<sub>cy</sub>). <sup>13</sup>C{<sup>1</sup>H}-APT NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz) &#x003b4;: 155.4 (s, CH<sub>thiouracil,3&#x02032;</sub>),
149.0 (s, CH<sub>py</sub>), 138.4 (s, CH<sub>py</sub>), 123.9 (s,
CH<sub>py</sub>), 123.9 (s, CH<sub>py</sub>), 123.8 (s, CH<sub>py</sub>), 123.8 (s, CH<sub>py</sub>), 110.0 (s, CH<sub>thiouracil,2&#x02032;</sub>), 69.4 (s, CH<sub>cy</sub>), 59.7 (s, CH<sub>cy</sub>), 51.0 (s,
CH<sub>2</sub>), 34.6 (s, CH<sub>2,cy</sub>), 32.9 (s, CH<sub>2,cy</sub>), 26.2 (s, CH<sub>2,cy</sub>), 25.9 (s, CH<sub>2,cy</sub>), 25.0
(s, CH<sub>2,cy</sub>). Elemental analysis (%): C<sub>23</sub>H<sub>32</sub>AuN<sub>5</sub>OS requires: C 44.30, H 5.17, N 11.23, S 5.14;
found: C 44.39, H 5.46, N 11.32, S 4.98. HRMS (ESI-QTOF) <italic>m</italic>/<italic>z</italic> (%): Calculated for C<sub>23</sub>H<sub>33</sub>AuN<sub>5</sub>OS, 624.2066; found, 624.2066 [M]<sup>+</sup>. IR:
&#x003bd; (C=N): 1662 cm<sup>&#x02013;1</sup>, &#x003bd; (NH): 2925
cm<sup>&#x02013;1</sup>, &#x003bd; (Au&#x02013;S): 404 cm<sup>&#x02013;1</sup>.</p><p><bold>3d</bold>: Yield = 68%. <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) &#x003b4;: 8.59&#x02013;8.50 (m, CH<sub>py,2</sub> + NH), 7.74 (td, CH<sub>py,4</sub>), 7.36 (d, CH<sub>py,5</sub>),
7.28 (td, CH<sub>py,3</sub>), 5.13&#x02013;4.93 (m, CH<sub>thioglucose</sub>), 4.88&#x02013;4.80 (m, CH<sub>cy</sub>), 4.41 (s, CH<sub>2</sub>), 4.18&#x02013;4.11 (m, CH<sub>cy</sub>), 4.101&#x02013;4.04 (m, CH<sub>2,thioglucose</sub>), 3.72&#x02013;3.67 (m, CH<sub>thioglucose</sub>), 2.0 (s, CH<sub>3</sub>), 2.0 (s, CH<sub>3</sub>), 1.9 (s, CH<sub>3</sub>), 1.9 (s, CH<sub>3</sub>), 1.78&#x02013;1.20 (m, CH<sub>2</sub>,<sub>cy</sub>). <sup>13</sup>C{<sup>1</sup>H}-APT NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz) &#x003b4;: 202.5 (s, C<sub>carbene</sub>),
170.9 (s, C<sub>C=O</sub>), 170.7 (s, C<sub>C=O</sub>), 169.9 (s, C<sub>C=O</sub>), 169.8 (s, C<sub>C=O</sub>), 156.6 (s, C<sub>ipso,py</sub>), 149.0 (s, CH<sub>py</sub>), 138.2
(s, CH<sub>py</sub>), 123.5 (s, CH<sub>py</sub>), 123.7 (s, CH<sub>py</sub>), 83.8 (s, CH<sub>thioglucose</sub>), 78.1 (s, CH<sub>thioglucose</sub>), 75.9 (s, CH<sub>thioglucose</sub>), 69.7 (s, CH<sub>py</sub>),
68.6 (s, CH<sub>thioglucose</sub>), 63.3 (s, CH<sub>2,thioglucose</sub>), 58.9 (s, CH<sub>py</sub>), 50.8 (s, CH<sub>thioglucose</sub>),
34.5 (s, CH<sub>2,cy</sub>), 26.4 (s, CH<sub>2,cy</sub>), 26.2 (s,
CH<sub>2,cy</sub>), 25.9 (s, CH<sub>2,cy</sub>), 25.8 (s, CH<sub>2,cy</sub>), 25.1 (s, CH<sub>2,cy</sub>), 24.9 (s, CH<sub>2,cy</sub>), 21.5
(s, CH<sub>3</sub>), 21.1 (s, CH<sub>3</sub>), 21.0 (s, CH<sub>3</sub>), 20.9 (s, CH<sub>3</sub>). Elemental analysis (%): C<sub>33</sub>H<sub>48</sub>AuN<sub>3</sub>O<sub>9</sub>S requires: C 46.10, H
5.63, N 4.89, S 3.73; found: C 46.33, H 5.52, N 4.77, S 3.67. HRMS
(ESI-QTOF) <italic>m</italic>/<italic>z</italic> (%): Calculated for
C<sub>33</sub>H<sub>48</sub>AuN<sub>3</sub>O<sub>9</sub>SNa, 882.2669;
found, 882.2761 [M + H]<sup>+</sup>. IR: &#x003bd; (C=N): 1557
cm<sup>&#x02013;1</sup>, &#x003bd; (NH): 2923 cm<sup>&#x02013;1</sup>,
&#x003bd; (Au&#x02013;S) 405 cm<sup>&#x02013;1</sup>.</p></sec></sec><sec id="sec4.2"><title>Cytotoxicity
Assay</title><p>The MTT assay was used to determine
cell viability as an indicator for cell sensitivity to the complexes.
Exponentially growing cells A549, HCT116 WT, HCT DKO Jurkat, MiaPaca2,
and healthy lymphocytes T were seeded at a density of approximately
1 &#x000d7; 10<sup>4</sup> cells per well in 96-well flat-bottomed microplates.
The complexes were dissolved in DMSO and then diluted with culture
medium to obtain the final concentrations ranging from 0.1 to 50 &#x003bc;M
in quadruplicate. Cells were incubated with the compounds for 24 h
at 37 &#x000b0;C. 10 &#x003bc;L of MTT (5 mg mL<sup>&#x02013;1</sup>) was
added to each well and plates were incubated for 2 h at 37 &#x000b0;C.
Then, media were discarded and DMSO (100 &#x003bc;L per well) was added
to dissolve the formazan precipitates in the plates. Plates containing
Jurkat were previously centrifuged for 15 min at 2500 rpm. Thereafter,
media were also eliminated, and DMSO (100 &#x003bc;L per well) was added.
The optical density was measured at 490 nm using a 96-well multiscanner
autoreader, UV&#x02013;visible ELISA. The IC<sub>50</sub> value was
calculated by nonlinear regression analysis using OriginPro.</p><sec id="sec4.2.1"><title>Cell Death
Study</title><p>Cell death was analyzed by measuring
the translocation of phosphatidylserine from the inner to outer cell
membrane. Cells Jurkat and Jurkat shBak were titrated with compounds <bold>2a</bold> and <bold>3d</bold> for 24 h at 37 &#x000b0;C. Then, they
were trypsinized and incubated at 37 &#x000b0;C for 15 min in ABB (140
mM NaCl, 2.5 mM CaCl<sub>2</sub>, 10 mM Hepes/NaOH, pH 7.4) containing
0.5 mg mL<sup>&#x02013;1</sup> of annexin V-DY634. Finally, cells were
diluted to 0.5 mL with ABB and analyzed by flow cytometry (FACSCalibur,
BD Biosciences, Spain).</p></sec><sec id="sec4.2.2"><title>DNA Binding</title><p>In DNA-binding experiments,
the complexes
were dissolved in DMSO and diluted with the Tris&#x02013;HCl buffer
(10 mM, pH = 7.2) with a final concentration of DMSO of 20%. The absorption
spectra were performed in fixed concentration of metal complexes (100
&#x003bc;M) while gradually increasing the concentration of CT-DNA from
0 to 100 &#x003bc;M. To obtain the absorption spectra, the required
amount of CT-DNA was added to both compound solution and the reference
solution to eliminate the absorbance of CT-DNA itself. Each sample
solution was allowed to equilibrate 10 min before the spectra were
recorded. Using the absorption titration data, the binding constant
K<sub>b</sub> was determined using the Wolfe&#x02013;Shimer equation:<sup><xref ref-type="bibr" rid="ref48">48</xref></sup><disp-formula id="uneq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_m001" position="anchor"/></disp-formula>where [DNA] is the concentration of CT-DNA,
&#x003b5;<sub>a</sub> corresponds to the extinction coefficient observed
(<italic>A</italic><sub>obsd</sub>/[M]), &#x003b5;<sub>f</sub> corresponds
to the coefficient of the free compound, &#x003b5;<sub>b</sub> is the
extinction coefficient of the compound fully bound to CT-DNA, and <italic>K</italic><sub>b</sub> is the intrinsic binding constant. The <italic>K</italic><sub>b</sub> value was determined by the ratio of the slope
to the intercept in the plot of [DNA]/(&#x003b5;<sub>a</sub> &#x02013;
&#x003b5;<sub>f</sub>) versus [DNA].</p></sec><sec id="sec4.2.3"><title>Thioredoxin Reductase Inhibition
Assay in A549 Cells</title><p>The thioredoxin reductase inhibition
assay for the compounds was
tested on A549 cells using a method reported by Holmgren et al.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> Briefly, cells were seeded in 24-well plates
at a density of 1 &#x000d7; 10<sup>5</sup> cells/well in DMEM/10% FBS.
After 48 h, they were treated with 3 &#x003bc;M of the compounds (<bold>2b</bold>, <bold>3b</bold>, <bold>3d</bold>, and auranofin) dissolved
in DMSO (0.1%) and one control (only 0.1% DMSO) and incubated at 37
&#x000b0;C, 5% CO<sub>2</sub> for 24 h. Following this, the media were
removed, and cells were washed twice with cold PBS and lysed with
ice-cold lysis buffer (50 mM Phosphate buffer pH 7.4; 1 mM EDTA, 0.1%
Triton-X 100) for 15 min on ice. The protein content in the samples
was estimated using the Bradford assay with bovine serum albumin (BSA)
as a calibration standard. Equal amounts of protein (5 &#x003bc;g) were
used. Samples were incubated with 30 &#x003bc;L of reaction mixture
(HEPES buffer (0.2 mM), insulin (3 mg/mL), NADPH (1 mM), EDTA (2 mM),
and either 5 &#x003bc;L of recombinant thioredoxin (1 mg/mL) or 5 &#x003bc;L
of HEPES buffer (200 &#x003bc;M)) for 30 min at 37 &#x000b0;C. The reaction
was stopped with 200 &#x003bc;L of stopping solution containing guanidine
hydrochloride (5.4 M in TRIS&#x02013;HCl 100 mM) and 5,5&#x02032;-dithio-bis(2-nitrobenzoic
acid) (1 mM). The absorbance was measured at 405 nm by using a FLUOstar
Omega (BMG LABTECH) plate reader. The difference in the absorbance
of samples containing Trx and buffer gave the activity of thioredoxin
reductase expressed as a percentage inhibition relative to the control.
The SD was calculated by using two independent experiments.</p></sec></sec><sec id="sec4.3"><title>Cell Death, Cell Cycle, ROS, and Mitochondrial Membrane Potential</title><p>200,000 cells (A549/mL) were seeded in flat-bottom 6-well plates
(1 mL/well) in complete medium and allowed to attach for 24 h. A solution
of the complex (<bold>3b</bold>) was added at a concentration of 4xIC<sub>50</sub> and A549 cells were cultured for a total of 24 h. The cells
were then deadhered with 200 &#x003bc;L of trypsin and resuspended in
1 mL of media. This cell suspension has been used for all flow cytometry
measurements that have been carried out at cytometer SA3800 Sony (cell
cycle) and cytometer GALLIOS Beckman Coulter. Commercial kits were
used for all flow cytometry studies and in all cases, they were used
as indicated in the manufacturer&#x02019;s instructions. Cell death
studies: ANNEXIN V FITC Apoptosis detection kit (immunostep, reference
ANXVKF-100T). Cell cycle: PI/RNASE Solution 200 test (immunostep,
reference PI/RNASE). ROS production: CellROX Green and CellROX Orange
Flow Cytometry Assay Kits (molecular probes by life technologies,
catalogue number C10492). Mitochondrial potential: MitoStep Flow Cytometry
Mitochondrial Membrane Potential Assay (immunostep, reference: MITO-100T).</p></sec><sec id="sec4.4"><title>Crystallography</title><p>Crystals were mounted in inert oil
on glass fibers and transferred to the cold gas stream of an Xcalibur
Oxford Diffraction (<bold>1a</bold>) or a Smart APEX CCD diffractometer
(<bold>1a&#x02032;</bold>, <bold>2a</bold>, <bold>3d</bold>) equipped
with a low-temperature attachment. Data were collected using monochromated
Mo-K&#x003b1; radiation (&#x003bb; = 0.71073 &#x000c5;). Scan type &#x003d6;.
Absorption corrections based on multiple scans were applied using
SADABS<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> or spherical harmonics implemented
in SCALE3 ABSPACK scaling algorithm.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> The
structures were solved by direct methods and refined on <italic>F</italic><sup>2</sup> using the program SHELXT-2018.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> All non-hydrogen atoms were refined anisotropically.</p></sec></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.inorgchem.5c00579?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.inorgchem.5c00579</ext-link>.<list id="silist" list-type="simple"><list-item><p>Additional experimental
details including NMR data,
X-ray data, stability studies by UV&#x02013;vis and NMR, mechanism
of cell death, and other flow cytometry studies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c00579/suppl_file/ic5c00579_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ic5c00579_si_001.pdf"><caption><p>ic5c00579_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes3"><title>Author Contributions</title><p><sup>&#x000a7;</sup> M.G.-M and
M.A.-L. contributed equally.</p></notes><notes notes-type="COI-statement" id="notes2"><p>The authors
declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>The authors thank project PID2022-136861NB-I00
funded
by MICIU/AEI10.13039/501100011033 and Gobierno de Arag&#x000f3;n (Research
Group E07_23R). Authors thank the Research Support Service of CEQMA
(CSIC) and SAI (Universidad de Zaragoza).</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="book" id="cit1"><person-group person-group-type="allauthors"><name><surname>Carver</surname><given-names>P. L.</given-names></name></person-group><article-title>Metals in Medicine:
The Therapeutic Use of Metal Ions in the Clinic</article-title>. In <source>Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal
Ions in the Clinic</source>; <person-group person-group-type="editor"><name><surname>Carver</surname><given-names>P. L.</given-names></name></person-group>, Ed.; <publisher-name>De Gruyter</publisher-name>: <publisher-loc>Berlin, Boston</publisher-loc>, <year>2019</year>; pp <fpage>1</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1515/9783110527872-001</pub-id>.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Mjos</surname><given-names>K. D.</given-names></name>; <name><surname>Orvig</surname><given-names>C.</given-names></name>
<article-title>Metallodrugs in Medicinal Inorganic
Chemistry</article-title>. <source>Chem. Rev.</source>
<year>2014</year>, <volume>114</volume>, <fpage>4540</fpage>&#x02013;<lpage>4563</lpage>. <pub-id pub-id-type="doi">10.1021/cr400460s</pub-id>.<pub-id pub-id-type="pmid">24456146</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Madec</surname><given-names>H.</given-names></name>; <name><surname>Figueiredo</surname><given-names>F.</given-names></name>; <name><surname>Cariou</surname><given-names>K.</given-names></name>; <name><surname>Roland</surname><given-names>S.</given-names></name>; <name><surname>Sollogoub</surname><given-names>M.</given-names></name>; <name><surname>Gasser</surname><given-names>G.</given-names></name>
<article-title>Metal Complexes for (Photo-)catalytic Reactions in
Living Cells and Organisms</article-title>. <source>Chem. Sci.</source>
<year>2023</year>, <volume>14</volume>, <fpage>409</fpage>&#x02013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1039/D2SC05672K</pub-id>.<pub-id pub-id-type="pmid">36741514</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Casini</surname><given-names>A.</given-names></name>; <name><surname>P&#x000f6;thig</surname><given-names>A.</given-names></name>
<article-title>Metals in Cancer Research: Beyond Platinum Metallodrugs</article-title>. <source>ACS Cent. Sci.</source>
<year>2024</year>, <volume>10</volume>, <fpage>242</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.3c01340</pub-id>.<pub-id pub-id-type="pmid">38435529</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Jin</surname><given-names>S.</given-names></name>; <name><surname>Muhammad</surname><given-names>N.</given-names></name>; <name><surname>Guo</surname><given-names>Z.</given-names></name>
<article-title><bold>S</bold>timuli-Responsive Therapeutic
Metallodrugs</article-title>. <source>Chem. Rev.</source>
<year>2019</year>, <volume>119</volume>, <fpage>1138</fpage>&#x02013;<lpage>1192</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00209</pub-id>.<pub-id pub-id-type="pmid">30299085</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Paprocka</surname><given-names>R.</given-names></name>; <name><surname>Wiese-Szadkowska</surname><given-names>M.</given-names></name>; <name><surname>Janciauskiene</surname><given-names>S.</given-names></name>; <name><surname>Kosmalski</surname><given-names>T.</given-names></name>; <name><surname>Kulik</surname><given-names>M.</given-names></name>; <name><surname>Helmin-Basa</surname><given-names>A.</given-names></name>
<article-title>Latest developments
in metal complexes
as anticancer agents</article-title>. <source>Coord. Chem. Rev.</source>
<year>2022</year>, <volume>452</volume>, <fpage>214307</fpage><pub-id pub-id-type="doi">10.1016/j.ccr.2021.214307</pub-id>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Englinger</surname><given-names>B.</given-names></name>; <name><surname>Pirker</surname><given-names>C.</given-names></name>; <name><surname>Heffeter</surname><given-names>P.</given-names></name>; <name><surname>Terenzi</surname><given-names>A.</given-names></name>; <name><surname>Kowol</surname><given-names>C. R.</given-names></name>; <name><surname>Keppler</surname><given-names>B. K.</given-names></name>; <name><surname>Berger</surname><given-names>W.</given-names></name>
<article-title>Metal Drugs and the
Anticancer Immune
Response</article-title>. <source>Chem. Rev.</source>
<year>2019</year>, <volume>119</volume>, <fpage>1519</fpage>&#x02013;<lpage>1624</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00396</pub-id>.<pub-id pub-id-type="pmid">30489072</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Chen</surname><given-names>Z. F.</given-names></name>; <name><surname>Orvig</surname><given-names>C.</given-names></name>; <name><surname>Liang</surname><given-names>H.</given-names></name>
<article-title>Multi-Target Metal-Based
Anticancer
Agents</article-title>. <source>Top Med. Chem.</source>
<year>2017</year>, <volume>17</volume>, <fpage>3131</fpage>&#x02013;<lpage>3145</lpage>. <pub-id pub-id-type="doi">10.2174/1568026617666171004155437</pub-id>.</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Kenny</surname><given-names>R. G.</given-names></name>; <name><surname>Marmion</surname><given-names>C. J.</given-names></name>
<article-title>Toward Multi-Targeted
Platinum and Ruthenium Drugs&#x02014;A
New Paradigm in Cancer Drug Treatment Regimens?</article-title>. <source>Chem. Rev.</source>
<year>2019</year>, <volume>119</volume>, <fpage>1058</fpage>&#x02013;<lpage>1137</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00271</pub-id>.<pub-id pub-id-type="pmid">30640441</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Lu</surname><given-names>Y.</given-names></name>; <name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Chang</surname><given-names>X.</given-names></name>; <name><surname>Liang</surname><given-names>Z.</given-names></name>; <name><surname>Lv</surname><given-names>L.</given-names></name>; <name><surname>Shan</surname><given-names>M.</given-names></name>; <name><surname>Lu</surname><given-names>Q.</given-names></name>; <name><surname>Wen</surname><given-names>Z.</given-names></name>; <name><surname>Gust</surname><given-names>R.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>
<article-title>Recent development
of gold(I) and gold(III) complexes as therapeutic agents for cancer
diseases</article-title>. <source>Chem. Soc. Rev.</source>
<year>2022</year>, <volume>51</volume>, <fpage>5518</fpage>&#x02013;<lpage>5556</lpage>. <pub-id pub-id-type="doi">10.1039/D1CS00933H</pub-id>.<pub-id pub-id-type="pmid">35699475</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Moreno-Alc&#x000e1;ntar</surname><given-names>G.</given-names></name>; <name><surname>Picchetti</surname><given-names>P.</given-names></name>; <name><surname>Casini</surname><given-names>A.</given-names></name>
<article-title>Gold Complexes in Anticancer Therapy:
From New Design Principles to Particle-Based Delivery Systems</article-title>. <source>Angew. Chem., Int. Ed. Engl.</source>
<year>2023</year>, <volume>62</volume>, <elocation-id>e202218000</elocation-id><pub-id pub-id-type="doi">10.1002/anie.202218000</pub-id>.<pub-id pub-id-type="pmid">36847211</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Mertens</surname><given-names>R. T.</given-names></name>; <name><surname>Gukathasan</surname><given-names>S.</given-names></name>; <name><surname>Arojojoye</surname><given-names>A. S.</given-names></name>; <name><surname>Olelewe</surname><given-names>C.</given-names></name>; <name><surname>Awuah</surname><given-names>S. G.</given-names></name>
<article-title>Next Generation
Gold Drugs and Probes: Chemistry and Biomedical Applications</article-title>. <source>Chem. Rev.</source>
<year>2023</year>, <volume>123</volume> (<issue>10</issue>), <fpage>6612</fpage>&#x02013;<lpage>6667</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.2c00649</pub-id>.<pub-id pub-id-type="pmid">37071737</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Salmain</surname><given-names>M.</given-names></name>; <name><surname>Bertrand</surname><given-names>B.</given-names></name>
<article-title>Emerging Anticancer Therapeutic Modalities
Brought
by Gold Complexes: Overview and Perspectives</article-title>. <source>Eur. J. Inorg. Chem.</source>
<year>2023</year>, <volume>26</volume>, <elocation-id>e202300340</elocation-id><pub-id pub-id-type="doi">10.1002/ejic.202300340</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Boyarskiy</surname><given-names>V. P.</given-names></name>; <name><surname>Luzyanin</surname><given-names>K. V.</given-names></name>; <name><surname>Kukushkin</surname><given-names>V. Y.</given-names></name>
<article-title>Acyclic diaminocarbenes (ADCs) as
a promising alternative to N-heterocyclic carbenes (NHCs) in transition
metal catalyzed organic transformations</article-title>. <source>Coord.
Chem. Rev.</source>
<year>2012</year>, <volume>256</volume>, <fpage>2029</fpage>&#x02013;<lpage>2056</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2012.04.022</pub-id>.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Kinzhalov</surname><given-names>M. A.</given-names></name>; <name><surname>Luzyanin</surname><given-names>K. V.</given-names></name>
<article-title>Reactivity of acyclic
diaminocarbene ligands</article-title>. <source>Coord. Chem. Rev.</source>
<year>2019</year>, <volume>399</volume>, <fpage>213014</fpage><pub-id pub-id-type="doi">10.1016/j.ccr.2019.213014</pub-id>.</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Bartolom&#x000e9;</surname><given-names>C.</given-names></name>; <name><surname>Ramiro</surname><given-names>Z.</given-names></name>; <name><surname>Garc&#x000ed;a-Cuadrado</surname><given-names>D.</given-names></name>; <name><surname>P&#x000e9;rez-Gal&#x000e1;n</surname><given-names>P.</given-names></name>; <name><surname>Raducan</surname><given-names>M.</given-names></name>; <name><surname>Bour</surname><given-names>C.</given-names></name>; <name><surname>Echavarren</surname><given-names>A. M.</given-names></name>; <name><surname>Espinet</surname><given-names>P.</given-names></name>
<article-title>Nitrogen Acyclic Gold(I) Carbenes:
Excellent and Easily
Accessible Catalysts in Reactions of 1,6-Enynes</article-title>. <source>Organometallics</source>
<year>2010</year>, <volume>29</volume>, <fpage>951</fpage>&#x02013;<lpage>956</lpage>. <pub-id pub-id-type="doi">10.1021/om901026m</pub-id>.</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Biasiolo</surname><given-names>L.</given-names></name>; <name><surname>Ciancaleoni</surname><given-names>G.</given-names></name>; <name><surname>Belpassi</surname><given-names>L.</given-names></name>; <name><surname>Bistoni</surname><given-names>G.</given-names></name>; <name><surname>Macchioni</surname><given-names>A.</given-names></name>; <name><surname>Tarantelli</surname><given-names>F.</given-names></name>; <name><surname>Zuccaccia</surname><given-names>D.</given-names></name>
<article-title>Relationship between the anion/cation
relative orientation and the catalytic activity of nitrogen acyclic
carbene&#x02013;gold catalysts</article-title>. <source>Catal. Sci. Technol.</source>
<year>2015</year>, <volume>5</volume>, <fpage>1558</fpage>&#x02013;<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1039/C4CY01440E</pub-id>.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Aliaga-Lavrijsen</surname><given-names>M.</given-names></name>; <name><surname>Herrera</surname><given-names>R. P.</given-names></name>; <name><surname>Villacampa</surname><given-names>M. D.</given-names></name>; <name><surname>Gimeno</surname><given-names>M. C.</given-names></name>
<article-title>Efficient Gold(I)
Acyclic Diaminocarbenes for the Synthesis of Propargylamines and Indolizines</article-title>. <source>ACS Omega</source>
<year>2018</year>, <volume>3</volume>, <fpage>9805</fpage>&#x02013;<lpage>9813</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.8b01352</pub-id>.<pub-id pub-id-type="pmid">31459109</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Hashmi</surname><given-names>A. S. K.</given-names></name>; <name><surname>Hengst</surname><given-names>T.</given-names></name>; <name><surname>Lothsch&#x000fc;tz</surname><given-names>C.</given-names></name>; <name><surname>Rominger</surname><given-names>F.</given-names></name>
<article-title>New and Easily Accessible
Nitrogen Acyclic Gold(I) Carbenes: Structure and Application in the
Gold-Catalyzed Phenol Synthesis as well as the Hydration of Alkynes</article-title>. <source>Adv. Synth. Catal.</source>
<year>2010</year>, <volume>352</volume>, <fpage>1315</fpage>&#x02013;<lpage>1337</lpage>. <pub-id pub-id-type="doi">10.1002/adsc.201000126</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Khrakovsky</surname><given-names>D. A.</given-names></name>; <name><surname>Tao</surname><given-names>C.</given-names></name>; <name><surname>Johnson</surname><given-names>M. W.</given-names></name>; <name><surname>Thornbury</surname><given-names>R. T.</given-names></name>; <name><surname>Shevick</surname><given-names>S. L.</given-names></name>; <name><surname>Toste</surname><given-names>F. D.</given-names></name>
<article-title>Enantioselective,
Stereodivergent Hydroazidation and Hydroamination of Allenes Catalyzed
by Acyclic Diaminocarbene (ADC) Gold(I) Complexes</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2016</year>, <volume>55</volume>, <fpage>6079</fpage>&#x02013;<lpage>6083</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201601550</pub-id>.</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Barbazanges</surname><given-names>M.</given-names></name>; <name><surname>Fensterbank</surname><given-names>L.</given-names></name>
<article-title>Chiral Acyclic Diaminocar- bene Complexes: a New Opportunity
for Gold Asymmetric Catalysis</article-title>. <source>ChemCatChem</source>
<year>2012</year>, <volume>4</volume>, <fpage>1065</fpage>&#x02013;<lpage>1066</lpage>. <pub-id pub-id-type="doi">10.1002/cctc.201200224</pub-id>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Bartolome</surname><given-names>C.</given-names></name>; <name><surname>Carrasco-Rando</surname><given-names>M.</given-names></name>; <name><surname>Coco</surname><given-names>S.</given-names></name>; <name><surname>Cordovilla</surname><given-names>C.</given-names></name>; <name><surname>Martin-Alvarez</surname><given-names>J. M.</given-names></name>; <name><surname>Espinet</surname><given-names>P.</given-names></name>
<article-title>Luminescent gold(I) carbenes from
2-pyridylisocyanide complexes: structural consequences of intramolecular
versus intermolecular hydrogen-bonding interactions</article-title>. <source>Inorg. Chem.</source>
<year>2008</year>, <volume>47</volume>, <fpage>1616</fpage>&#x02013;<lpage>1624</lpage>. <pub-id pub-id-type="doi">10.1021/ic702201e</pub-id>.<pub-id pub-id-type="pmid">18237121</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>R&#x000fa;bio</surname><given-names>G. M. D.
M.</given-names></name>; <name><surname>Keppler</surname><given-names>B. K.</given-names></name>; <name><surname>Chin</surname><given-names>J. M.</given-names></name>; <name><surname>Reithofer</surname><given-names>M. R.</given-names></name>
<article-title>Synthetically
Versatile Nitrogen Acyclic Carbene Stabilized GoldNanoparticles</article-title>. <source>Chem.&#x02014;Eur. J.</source>
<year>2020</year>, <volume>26</volume>, <fpage>15859</fpage>&#x02013;<lpage>15862</lpage>. <pub-id pub-id-type="doi">10.1002/chem.202003679</pub-id>.<pub-id pub-id-type="pmid">32996636</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Mora</surname><given-names>M.</given-names></name>; <name><surname>Gimeno</surname><given-names>M. C.</given-names></name>; <name><surname>Visbal</surname><given-names>R.</given-names></name>
<article-title>Recent advances in gold&#x02013;NHC
complexes with biological properties</article-title>. <source>Chem.
Soc. Rev.</source>
<year>2019</year>, <volume>48</volume>, <fpage>447</fpage>&#x02013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1039/C8CS00570B</pub-id>.<pub-id pub-id-type="pmid">30474097</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Porchia</surname><given-names>M.</given-names></name>; <name><surname>Pellei</surname><given-names>M.</given-names></name>; <name><surname>Marinelli</surname><given-names>M.</given-names></name>; <name><surname>Tisato</surname><given-names>F.</given-names></name>; <name><surname>Del Bello</surname><given-names>F.</given-names></name>; <name><surname>Santini</surname><given-names>C.</given-names></name>
<article-title>New insights in Au-NHCs
complexes as anticancer agents</article-title>. <source>Eur. J. Med.
Chem.</source>
<year>2018</year>, <volume>146</volume>, <fpage>709</fpage>&#x02013;<lpage>746</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2018.01.065</pub-id>.<pub-id pub-id-type="pmid">29407992</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Montanel-Perez</surname><given-names>S.</given-names></name>; <name><surname>Herrera</surname><given-names>R. P.</given-names></name>; <name><surname>Laguna</surname><given-names>A.</given-names></name>; <name><surname>Villacampa</surname><given-names>M. D.</given-names></name>; <name><surname>Gimeno</surname><given-names>M. C.</given-names></name>
<article-title>The fluxional amine gold(III) complex
as an excellent
catalyst and precursor of biologically active acyclic carbenes</article-title>. <source>Dalton Trans.</source>
<year>2015</year>, <volume>44</volume>, <fpage>9052</fpage>&#x02013;<lpage>9062</lpage>. <pub-id pub-id-type="doi">10.1039/C5DT00703H</pub-id>.<pub-id pub-id-type="pmid">25893402</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Montanel-P&#x000e9;rez</surname><given-names>S.</given-names></name>; <name><surname>Elizalde</surname><given-names>R.</given-names></name>; <name><surname>Laguna</surname><given-names>A.</given-names></name>; <name><surname>Villacampa</surname><given-names>M. D.</given-names></name>; <name><surname>Gimeno</surname><given-names>M. C.</given-names></name>
<article-title>Synthesis of Bioactive N-Acyclic Gold(I) and Gold(III)
Diamino Carbenes with Different Ancillary Ligands</article-title>. <source>Eur. J. Inorg. Chem.</source>
<year>2019</year>, <volume>2019</volume>, <fpage>4273</fpage>&#x02013;<lpage>4281</lpage>. <pub-id pub-id-type="doi">10.1002/ejic.201900606</pub-id>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Bertrand</surname><given-names>B.</given-names></name>; <name><surname>Romanov</surname><given-names>A. S.</given-names></name>; <name><surname>Brooks</surname><given-names>M.</given-names></name>; <name><surname>Davis</surname><given-names>J.</given-names></name>; <name><surname>Schmidt</surname><given-names>C.</given-names></name>; <name><surname>Ott</surname><given-names>I.</given-names></name>; <name><surname>O&#x02019;Connell</surname><given-names>M. A.</given-names></name>; <name><surname>Bochmann</surname><given-names>M.</given-names></name>
<article-title>Synthesis, structure
and cytotoxicity of cyclic (alkyl)(amino) carbene and acyclic carbene
complexes of group 11 metals</article-title>. <source>Dalton Trans.</source>
<year>2017</year>, <volume>46</volume>, <fpage>15875</fpage>&#x02013;<lpage>15887</lpage>. <pub-id pub-id-type="doi">10.1039/C7DT03189K</pub-id>.<pub-id pub-id-type="pmid">29114671</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Williams</surname><given-names>M.</given-names></name>; <name><surname>Green</surname><given-names>A. I.</given-names></name>; <name><surname>Fernandez-Cestau</surname><given-names>J.</given-names></name>; <name><surname>Hughes</surname><given-names>D. L.</given-names></name>; <name><surname>O&#x02019;Connell</surname><given-names>M. A.</given-names></name>; <name><surname>Searcey</surname><given-names>M.</given-names></name>; <name><surname>Bertrand</surname><given-names>B.</given-names></name>; <name><surname>Bochmann</surname><given-names>M.</given-names></name>
<article-title>(&#x00108;Np&#x01e91;C)Au<sup>III</sup> complexes of acyclic carbene ligands: synthesis and anticancer
properties</article-title>. <source>Dalton Trans.</source>
<year>2017</year>, <volume>46</volume>, <fpage>13397</fpage>&#x02013;<lpage>13408</lpage>. <pub-id pub-id-type="doi">10.1039/C7DT02804K</pub-id>.<pub-id pub-id-type="pmid">28945262</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Dietl</surname><given-names>M. C.</given-names></name>; <name><surname>Maag</surname><given-names>M.</given-names></name>; <name><surname>Ber</surname><given-names>S.</given-names></name>; <name><surname>Rominger</surname><given-names>F.</given-names></name>; <name><surname>Rudolph</surname><given-names>M.</given-names></name>; <name><surname>Caligiuri</surname><given-names>I.</given-names></name>; <name><surname>Andele</surname><given-names>P. K.</given-names></name>; <name><surname>Mkhalid</surname><given-names>I. A. I.</given-names></name>; <name><surname>Rizzolio</surname><given-names>F.</given-names></name>; <name><surname>Nogara</surname><given-names>P. A.</given-names></name>; <name><surname>Orian</surname><given-names>L.</given-names></name>; <name><surname>Scattolin</surname><given-names>T.</given-names></name>; <name><surname>Hashmi</surname><given-names>A. S. K.</given-names></name>
<article-title>Comparative study of the antiproliferative activity
of heterometallic carbene gold(I)&#x02013;platinum(II) and gold(I)&#x02013;palladium(II)
complexes in cancer cell lines</article-title>. <source>Chem. Sci.</source>
<year>2024</year>, <volume>15</volume>, <fpage>15291</fpage>&#x02013;<lpage>15298</lpage>. <pub-id pub-id-type="doi">10.1039/D4SC04585H</pub-id>.<pub-id pub-id-type="pmid">39246355</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Michelin</surname><given-names>R. A.</given-names></name>; <name><surname>Pombeiro</surname><given-names>A. J. L.</given-names></name>; <name><surname>Guedes Da Silva</surname><given-names>M. F.
C.</given-names></name>
<article-title>Aminocarbene complexes
derived from nucleophilic addition to isocyanide ligands</article-title>. <source>Coord. Chem. Rev.</source>
<year>2001</year>, <volume>218</volume>, <fpage>75</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/s0010-8545(01)00358-7</pub-id>.</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Boyarskiy</surname><given-names>V. P.</given-names></name>; <name><surname>Bokach</surname><given-names>N. A.</given-names></name>; <name><surname>Luzyanin</surname><given-names>K. V.</given-names></name>; <name><surname>Kukushkin</surname><given-names>V. Y.</given-names></name>
<article-title>Metal-mediated
and metal-catalyzed reactions of isocyanides</article-title>. <source>Chem. Rev.</source>
<year>2015</year>, <volume>115</volume>, <fpage>2698</fpage>&#x02013;<lpage>2779</lpage>. <pub-id pub-id-type="doi">10.1021/cr500380d</pub-id>.<pub-id pub-id-type="pmid">25740195</pub-id>
</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Lothsch&#x000fc;tz</surname><given-names>C.</given-names></name>; <name><surname>Wurm</surname><given-names>T.</given-names></name>; <name><surname>Zeiler</surname><given-names>A.</given-names></name>; <name><surname>Falkenhausen</surname><given-names>A. F. V.</given-names></name>; <name><surname>Rudolph</surname><given-names>M.</given-names></name>; <name><surname>Rominger</surname><given-names>F.</given-names></name>; <name><surname>Hashmi</surname><given-names>A. S. K.</given-names></name>
<article-title>Facile
Synthesis
of Functionalized Carbene Metal Complexes from Coordinated Isonitriles</article-title>. <source>Chem.&#x02014;Asian J.</source>
<year>2016</year>, <volume>11</volume>, <fpage>342</fpage>&#x02013;<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1002/asia.201500353</pub-id>.<pub-id pub-id-type="pmid">26033484</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Crespo</surname><given-names>O.</given-names></name>; <name><surname>Gimeno</surname><given-names>M. C.</given-names></name>; <name><surname>Laguna</surname><given-names>A.</given-names></name>; <name><surname>Montanel-P&#x000e9;rez</surname><given-names>S.</given-names></name>; <name><surname>Villacampa</surname><given-names>M. D.</given-names></name>
<article-title>Facile
Synthesis of Gold(III) Aryl&#x02013;Carbene Metallacycles</article-title>. <source>Organometallics</source>
<year>2012</year>, <volume>31</volume>, <fpage>5520</fpage>&#x02013;<lpage>5526</lpage>. <pub-id pub-id-type="doi">10.1021/om300495u</pub-id>.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Gimeno</surname><given-names>M.
C.</given-names></name>; <name><surname>Laguna</surname><given-names>A.</given-names></name>; <name><surname>Visbal</surname><given-names>R.</given-names></name>
<article-title>N-Heterocyclic Carbene Coinage Metal
Complexes as Intense Blue-Green Emitters</article-title>. <source>Organometallics</source>
<year>2012</year>, <volume>31</volume>, <fpage>7146</fpage>&#x02013;<lpage>7157</lpage>. <pub-id pub-id-type="doi">10.1021/om300571m</pub-id>.</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Johnson</surname><given-names>A.</given-names></name>; <name><surname>Gimeno</surname><given-names>M. C.</given-names></name>
<article-title>Synthesis of Propargyl-Functionalized NHC Gold Complexes</article-title>. <source>Organometallics</source>
<year>2017</year>, <volume>36</volume>, <fpage>1278</fpage>&#x02013;<lpage>1286</lpage>. <pub-id pub-id-type="doi">10.1021/acs.organomet.7b00012</pub-id>.</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Visbal</surname><given-names>R.</given-names></name>; <name><surname>Fern&#x000e1;ndez-Moreira</surname><given-names>V.</given-names></name>; <name><surname>Marzo</surname><given-names>I.</given-names></name>; <name><surname>Laguna</surname><given-names>A.</given-names></name>; <name><surname>Gimeno</surname><given-names>M. C.</given-names></name>
<article-title>Cytotoxicity and biodistribution studies of luminescent
Au(I) and Ag(I) N-heterocyclic carbenes. Searching for new biological
targets</article-title>. <source>Dalton Trans.</source>
<year>2016</year>, <volume>45</volume>, <fpage>15026</fpage>&#x02013;<lpage>15033</lpage>. <pub-id pub-id-type="doi">10.1039/C6DT02878K</pub-id>.<pub-id pub-id-type="pmid">27560479</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Frik</surname><given-names>M.</given-names></name>; <name><surname>Mart&#x000ed;nez</surname><given-names>A.</given-names></name>; <name><surname>Elie</surname><given-names>B. T.</given-names></name>; <name><surname>Gonzalo</surname><given-names>O.</given-names></name>; <name><surname>Ram&#x000ed;rez
de Mingo</surname><given-names>D.</given-names></name>; <name><surname>Sana&#x000fa;</surname><given-names>M.</given-names></name>; <name><surname>S&#x000e1;nchez-Delgado</surname><given-names>R.</given-names></name>; <name><surname>Sadhukha</surname><given-names>T.</given-names></name>; <name><surname>Prabha</surname><given-names>S.</given-names></name>; <name><surname>Ramos</surname><given-names>J. W.</given-names></name>; <name><surname>Marzo</surname><given-names>I.</given-names></name>; <name><surname>Contel</surname><given-names>M.</given-names></name>
<article-title>In Vitro and in Vivo Evaluation of Water-Soluble Iminophosphorane
Ruthenium(II) Compounds. A Potential Chemotherapeutic Agent for Triple
Negative Breast Cancer</article-title>. <source>J. Med. Chem.</source>
<year>2014</year>, <volume>57</volume>, <fpage>9995</fpage>&#x02013;<lpage>10012</lpage>. <pub-id pub-id-type="doi">10.1021/jm5012337</pub-id>.<pub-id pub-id-type="pmid">25409416</pub-id>
</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Tippayamontri</surname><given-names>T.</given-names></name>; <name><surname>Kotb</surname><given-names>R.</given-names></name>; <name><surname>Paquette</surname><given-names>B.</given-names></name>; <name><surname>Sanche</surname><given-names>L.</given-names></name>
<article-title>Cellular uptake and
cytoplasm/DNA distribution of cisplatin and oxaliplatin and their
liposomal formulation in human colorectal cancer cell HCT116</article-title>. <source>Invest. New Drugs</source>
<year>2011</year>, <volume>29</volume>, <fpage>1321</fpage>&#x02013;<lpage>1327</lpage>. <pub-id pub-id-type="doi">10.1007/s10637-010-9494-3</pub-id>.<pub-id pub-id-type="pmid">20658169</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Hatem</surname><given-names>E.</given-names></name>; <name><surname>Azzi</surname><given-names>S.</given-names></name>; <name><surname>El Banna</surname><given-names>N.</given-names></name>; <name><surname>He</surname><given-names>T.</given-names></name>; <name><surname>Heneman-Masurel</surname><given-names>A.</given-names></name>; <name><surname>Vernis</surname><given-names>L.</given-names></name>; <name><surname>Ba&#x000ef;lle</surname><given-names>D.</given-names></name>; <name><surname>Masson</surname><given-names>V.</given-names></name>; <name><surname>Dingli</surname><given-names>F.</given-names></name>; <name><surname>Loew</surname><given-names>D.</given-names></name>; <name><surname>Azzarone</surname><given-names>B.</given-names></name>; <name><surname>Eid</surname><given-names>P.</given-names></name>; <name><surname>Baldacci</surname><given-names>G.</given-names></name>; <name><surname>Huang</surname><given-names>M. E.</given-names></name>
<article-title>Auranofin/Vitamin C: A Novel Drug Combination Targeting
Triple-Negative Breast Cancer</article-title>. <source>JNCI</source>
<year>2019</year>, <volume>111</volume>, <fpage>597</fpage>&#x02013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djy149</pub-id>.<pub-id pub-id-type="pmid">30779852</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Cheng</surname><given-names>N.</given-names></name>; <name><surname>Zhang</surname><given-names>D.</given-names></name>; <name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>Lin</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Lin</surname><given-names>D.</given-names></name>
<article-title>Combination of Auranofin
and ICG-001 Suppress the Proliferation and Metastasis of Colon Cancer</article-title>. <source>Front. Oncol.</source>
<year>2021</year>, <volume>11</volume>, <fpage>738085</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.738085</pub-id>.<pub-id pub-id-type="pmid">34900688</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Cox</surname><given-names>A. G.</given-names></name>; <name><surname>Brown</surname><given-names>K. K.</given-names></name>; <name><surname>Arner</surname><given-names>E. S.</given-names></name>; <name><surname>Hampton</surname><given-names>M. B.</given-names></name>
<article-title>The thioredoxin
reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent
process that involves peroxiredoxin 3 oxidation</article-title>. <source>Biochem. Pharmacol.</source>
<year>2008</year>, <volume>76</volume>, <fpage>1097</fpage>&#x02013;<lpage>1109</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2008.08.021</pub-id>.<pub-id pub-id-type="pmid">18789312</pub-id>
</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Rios
Perez</surname><given-names>M. V.</given-names></name>; <name><surname>Roife</surname><given-names>D.</given-names></name>; <name><surname>Dai</surname><given-names>B.</given-names></name>; <name><surname>Pratt</surname><given-names>M.</given-names></name>; <name><surname>Dobrowolski</surname><given-names>R.</given-names></name>; <name><surname>Kang</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Augustine</surname><given-names>J. J.</given-names></name>; <name><surname>Zielinski</surname><given-names>R.</given-names></name>; <name><surname>Priebe</surname><given-names>W.</given-names></name>; <name><surname>Fleming</surname><given-names>J. B.</given-names></name>
<article-title>Antineoplastic effects
of auranofin in human pancreatic adenocarcinoma preclinical models</article-title>. <source>Surgery open science</source>
<year>2019</year>, <volume>1</volume>, <fpage>56</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.sopen.2019.05.004</pub-id>.<pub-id pub-id-type="pmid">33981979</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Gil-Moles</surname><given-names>M.</given-names></name>; <name><surname>Olmos</surname><given-names>M. E.</given-names></name>; <name><surname>Monge</surname><given-names>M.</given-names></name>; <name><surname>Beltr&#x000e1;n-Visiedo</surname><given-names>M.</given-names></name>; <name><surname>Marzo</surname><given-names>I.</given-names></name>; <name><surname>L&#x000f3;pez-de-Luzuriaga</surname><given-names>J. M.</given-names></name>; <name><surname>Concepci&#x000f3;n
Gimeno</surname><given-names>M.</given-names></name>
<article-title>Silver-based terpyridine complexes as antitumor agents</article-title>. <source>Chem.&#x02014;Eur. J.</source>
<year>2023</year>, <volume>29</volume>, <elocation-id>e202300116</elocation-id><pub-id pub-id-type="doi">10.1002/chem.202300116</pub-id>.<pub-id pub-id-type="pmid">36924425</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Gil-Moles</surname><given-names>M.</given-names></name>; <name><surname>Olmos</surname><given-names>M. E.</given-names></name>; <name><surname>L&#x000f3;pez-de-Luzuriaga</surname><given-names>J. M.</given-names></name>; <name><surname>Ott</surname><given-names>I.</given-names></name>; <name><surname>Gimeno</surname><given-names>M. C.</given-names></name>
<article-title>A dual approach to cancer treatment: gold(I) terpyridine
derivatives as DNA binders and inhibitors of mammalian thioredoxin
reductase</article-title>. <source>Inorg. Chem. Front.</source>
<year>2024</year>, <volume>11</volume>, <fpage>4802</fpage>&#x02013;<lpage>4814</lpage>. <pub-id pub-id-type="doi">10.1039/d4qi00755g</pub-id>.</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Holmgren</surname><given-names>A.</given-names></name>; <name><surname>Bj&#x000f6;rnstedt</surname><given-names>M.</given-names></name>
<article-title>Thioredoxin and thioredoxin reductase</article-title>. <source>Methods Enzymol.</source>
<year>1995</year>, <volume>252</volume>, <fpage>199</fpage>&#x02013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1016/0076-6879(95)52023-6</pub-id>.<pub-id pub-id-type="pmid">7476354</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Poerschke</surname><given-names>R. L.</given-names></name>; <name><surname>Moos</surname><given-names>P. J.</given-names></name>
<article-title>Thioredoxin reductase
1 knockdown enhances selenazolidine
cytotoxicity in human lung cancer cells via mitochondrial dysfunction</article-title>. <source>Biochem. Pharmacol.</source>
<year>2011</year>, <volume>81</volume>, <fpage>211</fpage>&#x02013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2010.09.024</pub-id>.<pub-id pub-id-type="pmid">20920480</pub-id>
</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Wolfe</surname><given-names>A. G.</given-names></name>; <name><surname>Shimer</surname><given-names>H.</given-names></name>; <name><surname>Meehan</surname><given-names>T.</given-names></name>
<article-title>Polycyclic
aromatic hydrocarbons
physically intercalate into duplex regions of denatured DNA</article-title>. <source>Biochem.</source>
<year>1987</year>, <volume>26</volume>, <fpage>6392</fpage>&#x02013;<lpage>6396</lpage>. <pub-id pub-id-type="doi">10.1021/bi00394a013</pub-id>.<pub-id pub-id-type="pmid">3427013</pub-id>
</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="computer-program" id="cit49"><person-group person-group-type="allauthors"><name><surname>Sheldrick</surname><given-names>G. M.</given-names></name></person-group><source>SADABS,
Program for Adsorption Correction</source>; <publisher-name>University
of G&#x000f6;ttingen</publisher-name>: <publisher-loc>G&#x000f6;ttingen,
Germany</publisher-loc>, <year>1996</year>.</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="computer-program" id="cit50"><person-group person-group-type="allauthors"><collab>CrysAlisPro</collab></person-group>. <source>Multi-scans Absorption Correction with SCALE3
ABSPACK Scaling Algorithm</source>. Version 1.171.35.11; <publisher-name>Agilent Technologies</publisher-name>.</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Sheldrick</surname><given-names>G. M.</given-names></name>
<article-title>Crystal
Structure Refinement with SHELXL</article-title>. <source>Acta Crystallogr.,
Sect. C: Struct. Chem.</source>
<year>2015</year>, <volume>C71</volume>, <fpage>3</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1107/S2053229614024218</pub-id>.</mixed-citation></ref></ref-list></back></article>